var title_f37_48_38656="Ganciclovir: Patient drug information";
var content_f37_48_38656=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ganciclovir: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/53/41811?source=see_link\">",
"       Ganciclovir (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/18/31012?source=see_link\">",
"       Ganciclovir (systemic): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11372 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-0DF129FE3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_48_38656=[""].join("\n");
var outline_f37_48_38656=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/53/41811?source=related_link\">",
"      Ganciclovir (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/18/31012?source=related_link\">",
"      Ganciclovir (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_48_38657="Trans fx medial sesamoid A";
var content_f37_48_38657=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse fracture of the medial sesamoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In contrast to a bipartite sesamoid, the fracture line (white arrow) is relatively straight, and the corners of the fragments are more abrupt and less rounded. The fracture borders are also less distinct than the adjacent edges of the partite sesamoid and lack a rim of cortication. Lack of cortication is easier to appreciate on the lateral view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_48_38657=[""].join("\n");
var outline_f37_48_38657=null;
var title_f37_48_38658="Ciprofloxacin (otic): Pediatric drug information";
var content_f37_48_38658=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ciprofloxacin (otic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?27/20/27971?source=see_link\">",
"    see \"Ciprofloxacin (otic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/21/15700?source=see_link\">",
"    see \"Ciprofloxacin (otic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9611245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cetraxal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10821267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Otic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Quinolone",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9611531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, otic, as hydrochloride [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cetraxal&reg;: 0.5 mg/0.25 mL (14s) [equivalent to ciprofloxacin base 0.2%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9611248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10821325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from intense light; protect from freezing",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10821304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute otitis externa due to susceptible strains of",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     or",
"     <i>",
"      Staphylococcus aureus",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9611552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cetraxal&reg; may be confused with cefTRIAXone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ciprofloxacin may be confused with cephalexin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9612500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Local: Application site pain, fungal superinfection, pruritus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10821305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ciprofloxacin, any component, or other quinolones",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10821307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Hypersensitivity reaction may occur with quinolone therapy; prolonged use may result in superinfection",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10821306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There have been reports of tendon inflammation and/or rupture with systemic quinolone antibiotic use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9611341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9611276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9779657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal studies; therefore, the manufacturer classifies ciprofloxacin otic as pregnancy category C. When administered orally or I.V., ciprofloxacin crosses the placenta. Refer to the Ciprofloxacin (Systemic) monograph for details. The amount of ciprofloxacin available systemically following topical application of the otic drops is expected to be significantly less in comparison to oral or I.V. doses.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10821326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits DNA-gyrase and topoisomerase I.V. in susceptible organisms; inhibits relaxation of supercoiled DNA and promotes breakage of double-stranded DNA",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10821327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/21/15700?source=see_link\">",
"      see \"Ciprofloxacin (otic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if tendon pain or swelling occurs, signs of allergy; burning, tingling, numbness, or weakness develops.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10821328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although fluoroquinolones are only FDA approved for use in children for complicated UTI, pyelonephritis, and postexposure treatment for inhalational anthrax, the AAP has provided a list of other possible uses for fluoroquinolones once risks and benefits have been assessed to justify its use:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     &bull; Chronic suppurative otitis media or otitis externa caused by",
"     <i>",
"      P. aeruginosa",
"     </i>",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15952 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-AA4CF5E739-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_48_38658=[""].join("\n");
var outline_f37_48_38658=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611245\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10821267\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611531\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611248\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10821325\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10821304\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611552\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9612500\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10821305\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10821307\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10821306\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299046\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611341\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611276\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9779657\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10821326\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10821327\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10821328\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15952\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15952|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/7/26740?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?35/39/36468?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/50/6947?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/20/27971?source=related_link\">",
"      Ciprofloxacin (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/21/15700?source=related_link\">",
"      Ciprofloxacin (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/5/20570?source=related_link\">",
"      Ciprofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/11/17590?source=related_link\">",
"      Ciprofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?43/11/44216?source=related_link\">",
"      Ciprofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_48_38659="Telavancin: Patient drug information";
var content_f37_48_38659=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Telavancin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/42/27301?source=see_link\">",
"     see \"Telavancin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8119746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vibativ&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700271",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug if you are pregnant. A pregnancy test will be done to show that you are NOT pregnant before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700313",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you get pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705270",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to telavancin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Foamy urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698647",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       During the infusion, a rash on the face, neck, trunk, and arms.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12310 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-481E12C6DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_48_38659=[""].join("\n");
var outline_f37_48_38659=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119746\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030593\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030595\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030594\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030598\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030599\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030601\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030597\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030603\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/42/27301?source=related_link\">",
"      Telavancin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_48_38660="Acyclovir (systemic): Patient drug information";
var content_f37_48_38660=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Acyclovir (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/40/37512?source=see_link\">",
"     see \"Acyclovir (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/37/2649?source=see_link\">",
"     see \"Acyclovir (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7808291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zovirax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7808292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Acyclovir&reg;;",
"     </li>",
"     <li>",
"      Mylan-Acyclovir;",
"     </li>",
"     <li>",
"      Nu-Acyclovir;",
"     </li>",
"     <li>",
"      ratio-Acyclovir;",
"     </li>",
"     <li>",
"      Teva-Acyclovir;",
"     </li>",
"     <li>",
"      Zovirax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691508",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat herpes infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat chickenpox.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701438",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to acyclovir, valacyclovir, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug for an infection that came back, start this drug as soon as you can.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695174",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug for herpes zoster, start it as soon as you can; no later than 3 days after the rash shows up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug for chickenpox, start it as soon as you can; no later than 24 hours after the rash shows up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to store the shot closely. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12337 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-9C98E7F444-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_48_38660=[""].join("\n");
var outline_f37_48_38660=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7808291\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7808292\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030874\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030873\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030878\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030879\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030881\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030876\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030877\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030882\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030883\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_international\" href=\"mobipreview.htm?17/42/18081?source=related_link\">",
"      Acyclovir (ophthalmic): International drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?36/40/37512?source=related_link\">",
"      Acyclovir (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/37/2649?source=related_link\">",
"      Acyclovir (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/27/1460?source=related_link\">",
"      Acyclovir (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/60/40899?source=related_link\">",
"      Acyclovir (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/51/9011?source=related_link\">",
"      Acyclovir (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_48_38661="Clinical manifestations and diagnosis of obesity hypoventilation syndrome";
var content_f37_48_38661=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of obesity hypoventilation syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/48/38661/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/48/38661/contributors\">",
"     Paul M Suratt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/48/38661/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/48/38661/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/48/38661/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/48/38661/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/48/38661/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity Hypoventilation Syndrome (OHS) exists when an obese individual (body mass index (BMI)",
"    <span class=\"nowrap\">",
"     &gt;30kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    has awake alveolar hypoventilation (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    &gt;45 mmHg), which cannot be attributed to other conditions such as pulmonary disease, skeletal restriction, neuromuscular weakness, hypothyroidism, or pleural pathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38661/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Most patients with OHS present with chronic hypoventilation, although some may develop acute cardiopulmonary compromise. Prompt diagnosis and therapy are important to avoid the adverse effects of OHS, especially since untreated patients with OHS have a high mortality rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38661/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of OHS are reviewed here, while the pathogenesis and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21541?source=see_link\">",
"     \"Pathogenesis of obesity hypoventilation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/32/29192?source=see_link\">",
"     \"Treatment of the obesity hypoventilation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/5/12375?source=see_link\">",
"     \"Noninvasive positive pressure therapy of the obesity hypoventilation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with OHS are obese (BMI &gt;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    and most have coexisting obstructive sleep apnea (OSA). The most common symptoms and signs are due to the coexisting OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38661/abstract/6\">",
"     6",
"    </a>",
"    ], which include excessive daytime sleepiness, loud snoring, choking during sleep, resuscitative snorting (ie, a loud snort that follows an apnea as the patient partially awakens and reopens the upper airway), fatigue, hypersomnolence, impaired concentration and memory, a small oropharynx, and a thick neck [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38661/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many patients have symptoms and signs of pulmonary hypertension with right-sided heart failure (eg, elevated jugular venous pressure, hepatomegaly, and pedal edema) and, occasionally, a plethoric complexion from polycythemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38661/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. Patients can also present with hypercapnic respiratory failure of unknown etiology. Generally speaking, patients with OHS tend to have more comorbidities than patients with eucapnic obesity, including systemic hypertension, heart failure, angina, and insulin resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38661/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It can be difficult to distinguish individuals who have both OHS and OSA from individuals who have OSA alone. Dyspnea on exertion is a clue that OHS is present because patients with OSA alone generally do not develop dyspnea on exertion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38661/abstract/1,4,7,9\">",
"     1,4,7,9",
"    </a>",
"    ]. Severe obesity (BMI &gt;50",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    is another clue that OHS may be present, since nearly 50 percent of such individuals have OHS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38661/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7910647\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic testing is necessary for the evaluation of suspected OHS. In this section, we review the common diagnostic tests, including arterial blood gases, pulmonary function tests, polysomnography, chest radiographs, electrocardiography, and echocardiography. The role of these tests in the evaluation of suspected OHS is described in the next section. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Diagnostic approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Arterial blood gases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial blood gas testing must be performed, since hypercapnia must be identified to diagnose OHS. The following abnormalities occur in patients with OHS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypercapnia (PaCO",
"      <sub>",
"       2",
"      </sub>",
"      &gt;45 mmHg) is always present during wakefulness. The PaCO",
"      <sub>",
"       2",
"      </sub>",
"      can be reduced or normalized, however, by voluntary hyperventilation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38661/abstract/10\">",
"       10",
"      </a>",
"      ]. It can also be reduced or normalized by involuntary hyperventilation caused by the arterial blood gas procedure.",
"     </li>",
"     <li>",
"      Hypoxemia (PaO",
"      <sub>",
"       2",
"      </sub>",
"      &lt;70 mmHg) is usually present. The calculated alveolar-arterial (A-a) oxygen gradient may be normal when there is no coexisting lung or heart disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38661/abstract/1,11-13\">",
"       1,11-13",
"      </a>",
"      ]. An elevated hematocrit is common and may be a clue that the patient is hypoxemic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38661/abstract/4,14\">",
"       4,14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27028507\">",
"    <span class=\"h2\">",
"     Serum bicarbonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high serum bicarbonate level is a clue that the patient is chronically hypercapnic. This test is helpful if arterial blood gases cannot be obtained or are delayed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38661/abstract/6,15\">",
"     6,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary use of pulmonary function tests is to exclude obstructive lung disease. Most patients with OHS have pulmonary function tests that are characteristic of obesity. These include a low forced vital capacity (FVC), a low forced expiratory volume in one second (FEV1), a normal",
"    <span class=\"nowrap\">",
"     FEV1/FVC",
"    </span>",
"    ratio, and a low expiratory reserve volume (ERV) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38661/abstract/7,14,16\">",
"     7,14,16",
"    </a>",
"    ]. Total lung capacity (TLC) may also be diminished in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38661/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Polysomnography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with OHS have an abnormal number of apneas and hypopneas per hour of sleep (ie, a high apnea hypopnea index [AHI]) due to coexisting OSA. The converse is not true; an elevated AHI does not predict the presence of coexisting OHS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38661/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, patients with OHS usually have more profound oxyhemoglobin desaturation during sleep than patients with OSA alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38661/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28885499\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;On a routine chest radiograph, both hemidiaphragms are usually elevated due to the obese abdomen and the heart is frequently enlarged due to right ventricular hypertrophy. Asymmetrical elevation of a hemidiaphragm suggests diaphragmatic paralysis, another condition that can cause hypoventilation. Hyperinflation and bullous disease suggest that the chronic hypercapnia may be due to pulmonary disease rather than OHS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28885553\">",
"    <span class=\"h2\">",
"     Cardiac studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with OHS often have an abnormal electrocardiogram (ECG), echocardiogram,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiac catheterization. The ECG and echocardiogram may show right atrial and right ventricular hypertrophy, while the cardiac catheterization frequently reveals pulmonary hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38661/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2041?source=see_link\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation should be performed quickly because untreated OHS is associated with high mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38661/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In this section, we describe our approach to the evaluation of suspected OHS. The pertinent diagnostic tests are reviewed above. (See",
"    <a class=\"local\" href=\"#H7910647\">",
"     'Diagnostic tests'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    OHS is diagnosed when the following criteria are confirmed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obesity (BMI be &gt;30",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"     </li>",
"     <li>",
"      Awake alveolar hypoventilation (PaCO",
"      <sub>",
"       2",
"      </sub>",
"      &gt;45 mmHg)",
"     </li>",
"     <li>",
"      An alternative cause of the hypoventilation cannot be identified",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The absence of an alternative cause of hypoventilation is an important requirement for the diagnosis of OHS. In clinical practice, patients frequently have additional diseases that cause hypoventilation (eg, COPD). If the other disease is mild and unlikely to cause hypercapnia, then it is reasonable to give the patient a diagnosis of OHS. If the other disease is more severe and probably contributing to hypercapnia, the situation becomes more complicated. In this setting, OHS cannot be diagnosed with certainty. However, if the patient has severe obesity, severe sleep apnea, and severe oxyhemoglobin desaturation during sleep, we generally presume that OHS may be contributing and treat the patient accordingly.",
"   </p>",
"   <p>",
"    All individuals with suspected OHS should have their BMI measured and arterial blood gases (ABGs) performed. The purpose of the ABGs is to confirm alveolar hypoventilation. ABGs are most helpful when performed while the patient is breathing room air because the A-a oxygen gradient can be calculated. A normal A-a oxygen gradient excludes pulmonary parenchymal or airways disease.",
"   </p>",
"   <p>",
"    Additional testing is necessary to exclude other diseases that can cause alveolar hypoventilation, such as chronic obstructive pulmonary disease (COPD), restrictive disease (eg, neuromuscular weakness, interstitial lung disease, chest wall disease), hypothyroidism, and diaphragmatic paralysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38661/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. This generally requires the following tests:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thyroid function tests and serum electrolytes (including magnesium and phosphorus) to look for hypothyroidism and electrolyte-related neuromuscular weakness, respectively. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3608?source=see_link\">",
"       \"Laboratory assessment of thyroid function\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42580?source=see_link\">",
"       \"Signs and symptoms of magnesium depletion\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32659?source=see_link\">",
"       \"Signs and symptoms of hypophosphatemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary function tests, including spirometry, lung volumes, diffusing capacity, and inspiratory and expiratory pressures, to look for evidence that COPD or a restrictive disease may be a prominent contributor to the alveolar hypoventilation. In patients with severe respiratory failure, these tests will need to be deferred until the patients are stabilized. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=see_link\">",
"       \"Overview of pulmonary function testing in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/18/11560?source=see_link\">",
"       \"Tests of respiratory muscle strength\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A chest radiograph to look for parenchymal lung disease, chest wall disease, asymmetrical elevation of a hemidiaphragm (ie, diaphragm paralysis), and cardiomegaly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although polysomnography is not required for the diagnosis of OHS, it should be performed in all patients with OHS for several reasons. First, in-laboratory polysomnography is the gold-standard diagnostic test for OSA, which frequently coexists with OHS and should be both identified and treated. Second, positive airway pressure therapy, the preferred treatment for OHS, can be titrated during polysomnography. Finally, polysomnography can give the clinician an impression of disease severity by determining the severity and duration of oxyhemoglobin desaturation, as well as the presence of cardiac dysrhythmias. The role of level 3 portable monitoring rather than in-laboratory polysomnography in OHS is unclear.",
"   </p>",
"   <p>",
"    The preceding discussion assumes that the patient with suspected OHS presented with chronic alveolar hypoventilation. However, presentation with acute or chronic hypercapnic respiratory failure is also common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38661/abstract/6\">",
"     6",
"    </a>",
"    ]. When a patient presents with severe acute respiratory failure due to OHS, diagnostic polysomnography with positive airway pressure titration during the same night is optimal if the patient is stable enough to go to the sleep laboratory. However, the diagnostic evaluation may need to be postponed and therapy immediately initiated if the patient is not well enough to go to the sleep laboratory. Overnight oximetry is a reasonable surrogate diagnostic test in this situation. Significant oxyhemoglobin desaturation not corrected by oxygen administration after several hours of recording should prompt empiric positive airway pressure therapy. The treatment of OHS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/32/29192?source=see_link\">",
"     \"Treatment of the obesity hypoventilation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/5/12375?source=see_link\">",
"     \"Noninvasive positive pressure therapy of the obesity hypoventilation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, acute pulmonary embolism is a frequent cause of death in patients with OHS. Therefore, a diagnostic evaluation should be pursued whenever thrombophlebitis or pulmonary embolism is suspected. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link&amp;anchor=H27#H27\">",
"     \"Diagnosis of acute pulmonary embolism\", section on 'Diagnostic approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7910704\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obesity Hypoventilation Syndrome (OHS) exists when an obese individual (body mass index (BMI)",
"      <span class=\"nowrap\">",
"       &gt;30kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      has awake alveolar hypoventilation (PaCO",
"      <sub>",
"       2",
"      </sub>",
"      &gt;45 mmHg), which cannot be attributed to other conditions, such as pulmonary parenchymal disease, skeletal restriction, neuromuscular weakness, hypothyroidism, or pleural pathology. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with OHS are obese and most have coexisting obstructive sleep apnea (OSA). The most common symptoms and signs are due to the coexisting OSA, which include excessive daytime sleepiness, loud snoring, choking during sleep, resuscitative snoring, fatigue, hypersomnolence, impaired concentration and memory, a small oropharynx, and a thick neck. Some patients present with hypercapnic respiratory failure or uncertain etiology. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic testing is necessary for the evaluation of suspected OHS. Commonly performed diagnostic tests include arterial blood gases, pulmonary function tests, polysomnography, and chest radiographs. (See",
"      <a class=\"local\" href=\"#H7910647\">",
"       'Diagnostic tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic evaluation should be performed quickly because untreated OHS is associated with high mortality. All individuals with suspected OHS should have arterial blood gases (ABGs) performed. The purpose of the ABGs is to confirm alveolar hypoventilation. Additional testing is necessary to exclude other diseases that can cause alveolar hypoventilation, such as chronic obstructive pulmonary disease (COPD), restrictive disease (eg, neuromuscular weakness, interstitial lung disease, chest wall disease), hypothyroidism, and diaphragmatic paralysis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/1\">",
"      BICKELMANN AG, BURWELL CS, ROBIN ED, WHALEY RD. Extreme obesity associated with alveolar hypoventilation; a Pickwickian syndrome. Am J Med 1956; 21:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/2\">",
"      Mokhlesi B, Kryger MH, Grunstein RR. Assessment and management of patients with obesity hypoventilation syndrome. Proc Am Thorac Soc 2008; 5:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/3\">",
"      Chouri-Pontarollo N, Borel JC, Tamisier R, et al. Impaired objective daytime vigilance in obesity-hypoventilation syndrome: impact of noninvasive ventilation. Chest 2007; 131:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/4\">",
"      Nowbar S, Burkart KM, Gonzales R, et al. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med 2004; 116:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/5\">",
"      Miller A, Granada M. In-hospital mortality in the Pickwickian syndrome. Am J Med 1974; 56:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/6\">",
"      Mokhlesi B. Obesity hypoventilation syndrome: a state-of-the-art review. Respir Care 2010; 55:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/7\">",
"      P&eacute;rez de Llano LA, Golpe R, Ortiz Piquer M, et al. Short-term and long-term effects of nasal intermittent positive pressure ventilation in patients with obesity-hypoventilation syndrome. Chest 2005; 128:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/8\">",
"      Piper AJ, Grunstein RR. Obesity hypoventilation syndrome: mechanisms and management. Am J Respir Crit Care Med 2011; 183:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/9\">",
"      Kessler R, Chaouat A, Schinkewitch P, et al. The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases. Chest 2001; 120:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/10\">",
"      Leech JA, Onal E, Baer P, Lopata M. Determinants of hypercapnia in occlusive sleep apnea syndrome. Chest 1987; 92:807.",
"     </a>",
"    </li>",
"    <li>",
"     Rochester, DF, Arora, NS. Respiratory failure from obesity. In: Medical Complications of Obesity, Mancini, M, Lewis, B, Contaldo, F (Eds), Academic Press, London 1980. p.183.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/12\">",
"      Zwillich CW, Sutton FD, Pierson DJ, et al. Decreased hypoxic ventilatory drive in the obesity-hypoventilation syndrome. Am J Med 1975; 59:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/13\">",
"      Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999; 22:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/14\">",
"      Heinemann F, Budweiser S, Dobroschke J, Pfeifer M. Non-invasive positive pressure ventilation improves lung volumes in the obesity hypoventilation syndrome. Respir Med 2007; 101:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/15\">",
"      Mokhlesi B, Tulaimat A, Faibussowitsch I, et al. Obesity hypoventilation syndrome: prevalence and predictors in patients with obstructive sleep apnea. Sleep Breath 2007; 11:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/16\">",
"      Akashiba T, Akahoshi T, Kawahara S, et al. Clinical characteristics of obesity-hypoventilation syndrome in Japan: a multi-center study. Intern Med 2006; 45:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/17\">",
"      Banerjee D, Yee BJ, Piper AJ, et al. Obesity hypoventilation syndrome: hypoxemia during continuous positive airway pressure. Chest 2007; 131:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/18\">",
"      Jones JB, Wilhoit SC, Findley LJ, Suratt PM. Oxyhemoglobin saturation during sleep in subjects with and without the obesity-hypoventilation syndrome. Chest 1985; 88:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/19\">",
"      Kaw R, Hernandez AV, Walker E, et al. Determinants of hypercapnia in obese patients with obstructive sleep apnea: a systematic review and metaanalysis of cohort studies. Chest 2009; 136:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/20\">",
"      Martin TJ, Sanders MH. Chronic alveolar hypoventilation: a review for the clinician. Sleep 1995; 18:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/21\">",
"      Lin CC, Tsan KW, Chen PJ. The relationship between sleep apnea syndrome and hypothyroidism. Chest 1992; 102:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38661/abstract/22\">",
"      Grunstein RR, Sullivan CE. Sleep apnea and hypothyroidism: mechanisms and management. Am J Med 1988; 85:775.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7698 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-3384FBAA07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_48_38661=[""].join("\n");
var outline_f37_48_38661=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7910704\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7910647\">",
"      DIAGNOSTIC TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27028507\">",
"      Serum bicarbonate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Polysomnography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28885499\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28885553\">",
"      Cardiac studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7910704\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3608?source=related_link\">",
"      Laboratory assessment of thyroid function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/5/12375?source=related_link\">",
"      Noninvasive positive pressure therapy of the obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/2/21541?source=related_link\">",
"      Pathogenesis of obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32659?source=related_link\">",
"      Signs and symptoms of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42580?source=related_link\">",
"      Signs and symptoms of magnesium depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/18/11560?source=related_link\">",
"      Tests of respiratory muscle strength",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/32/29192?source=related_link\">",
"      Treatment of the obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_48_38662="Ovarian hyperthecosis";
var content_f37_48_38662=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ovarian hyperthecosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/48/38662/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/48/38662/contributors\">",
"     Andr&eacute; P van Beek, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/48/38662/contributors\">",
"     Jolande A Land, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/48/38662/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/48/38662/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/48/38662/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/48/38662/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/48/38662/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/48/38662/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term hyperthecosis refers to the presence of nests of luteinized theca cells in the ovarian stroma due to differentiation of the ovarian interstitial cells into steroidogenically active luteinized stromal cells (",
"    <a class=\"graphic graphic_picture graphicRef75548 \" href=\"mobipreview.htm?38/62/39909\">",
"     picture 1",
"    </a>",
"    ). These nests or islands of luteinized theca cells are scattered throughout the stroma of the ovary, rather than being confined to areas around cystic follicles as in the polycystic ovary syndrome (PCOS). The result is greater production of androgens. The precise etiology of ovarian hyperthecosis is still unclear.",
"   </p>",
"   <p>",
"    The clinical presentation, diagnosis, and treatment of ovarian hyperthecosis are discussed here. The clinical presentation and diagnosis of polycystic ovary syndrome are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14632347\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian hyperthecosis, a disorder characterized by severe hyperandrogenism and insulin resistance, is seen primarily in postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Women typically present with slowly progressive acne and hirsutism (eg, excessive male pattern hair growth), and they are likely to be virilized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, many have clitoral enlargement, male pattern baldness, deepening of the voice, and a male habitus.",
"   </p>",
"   <p>",
"    In almost all cases, insulin resistance and hyperinsulinemia are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ], and women are at increased risk for type 2 diabetes and cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/2\">",
"     2",
"    </a>",
"    ]. Additional physical findings may include central obesity, skin tags, and acanthosis nigricans.",
"   </p>",
"   <p>",
"    The ovarian secretion of large amounts of androgens in women with hyperthecosis means that peripheral estrogen production is increased. As a result, the risk of endometrial hyperplasia and endometrial carcinoma is increased, especially in postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/2,7\">",
"     2,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among premenopausal women who present with hyperandrogenism, the vast majority have polycystic ovary syndrome (PCOS) and, only rarely, ovarian hyperthecosis. These disease entities may be difficult to distinguish from each other, and may all be part of the same spectrum of hyperandrogenic conditions. However, the hirsutism and insulin resistance are more severe in women with ovarian hyperthecosis compared with those with PCOS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H952680715\">",
"    <span class=\"h2\">",
"     Biochemical findings",
"    </span>",
"   </p>",
"   <p>",
"    Patients with hyperthecosis typically have the following biochemical findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum total testosterone concentrations &gt;150",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (&gt;5.2",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/8-11\">",
"       8-11",
"      </a>",
"      ]. It is the single most important biochemical finding and it should prompt imaging of adrenals and ovaries. It is generally believed that testosterone below 5.2",
"      <span class=\"nowrap\">",
"       nmol/L",
"      </span>",
"      rules out ovarian hyperthecosis, although no solid data are available to substantiate this.",
"     </li>",
"     <li>",
"      Insulin resistance and hyperinsulinemia that are sometimes severe [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/5\">",
"       5",
"      </a>",
"      ]; the latter can cause an increase in ovarian androgen production which may be mediated by binding to insulin-like growth factor 1 receptors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28567?source=see_link\">",
"       \"Insulin resistance: Definition and clinical spectrum\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"       \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Normal or suppressed LH and FSH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Normal serum dehydroepiandrosterone (DHEA) or dehydroepiandrosterone sulfate (DHEA sulfate) concentrations.",
"     </li>",
"     <li>",
"      Normal 17(OH) progesterone concentrations: Basal &lt;6",
"      <span class=\"nowrap\">",
"       nmol/L",
"      </span>",
"      (200",
"      <span class=\"nowrap\">",
"       ng/dL);",
"      </span>",
"      60 minutes post-ACTH (250 mcg) &lt;30",
"      <span class=\"nowrap\">",
"       nmol/L",
"      </span>",
"      (1000",
"      <span class=\"nowrap\">",
"       ng/dL).",
"      </span>",
"      In regularly cycling women determination of 17(OH) progesterone is performed in the follicular phase.",
"     </li>",
"     <li>",
"      Normal prolactin and IGF-1.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H952680501\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In case of an increased testosterone concentration &gt;150",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (or &gt;5.2",
"    <span class=\"nowrap\">",
"     nmol/L),",
"    </span>",
"    additional imaging is mandatory to find the source of androgen production. (See",
"    <a class=\"local\" href=\"#H14632553\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H952680508\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography in women with hyperthecosis usually shows a bilateral increase in ovarian stroma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Unlike PCOS, where the ovaries characteristically have a multifollicular appearance with 12 or more antral follicles of 2 to 9 mm per ovary",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ovarian volume &gt;10 cm",
"    <sup>",
"     3",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/16\">",
"     16",
"    </a>",
"    ], few cysts are seen in severe hyperthecosis and the ovaries appear more solid (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68176 \" href=\"mobipreview.htm?25/28/26049\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/14\">",
"     14",
"    </a>",
"    ]. In postmenopausal women with hyperthecosis, ovarian size is usually increased compared to normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H952680515\">",
"    <span class=\"h3\">",
"     MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normal postmenopausal ovary has a mean volume between 1.25 to 3.7 cm",
"    <sup>",
"     3",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], and in hyperthecosis the average volume may be up to 10 cm",
"    <sup>",
"     3",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/6,17\">",
"     6,17",
"    </a>",
"    ]. MRI findings in ovarian hyperthecosis include symmetric bilateral ovarian enlargement, with homogeneous T2-hypointensity and mild enhancement of the ovaries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H171735164\">",
"    <span class=\"h3\">",
"     Additional testing",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GnRH agonist testing &mdash; We suggest administering a single dose of long-acting GnRH-agonists for diagnostic purposes in patients with increased testosterone concentrations &gt;5.2",
"      <span class=\"nowrap\">",
"       nmol/L",
"      </span>",
"      in whom the diagnosis of hyperthecosis is considered based on biochemical findings and imaging. This may be especially relevant in the context of a concomitant adrenal &ldquo;incidentaloma&rdquo; on imaging, which may occur in 4 to 10 percent of patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=see_link\">",
"       \"Clinical presentation and evaluation of adrenocortical tumors\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Immediately before and four weeks after intramuscular injection of a GnRH-agonist testosterone, LH and FSH should be determined. Suppression of testosterone confirms the presence of LH-dependent ovarian testosterone production and may provide evidence for successful long-term treatment with GnRH-agonists [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/22-25\">",
"       22-25",
"      </a>",
"      ]. However, this test does",
"      <strong>",
"       not",
"      </strong>",
"      distinguish between hyperthecosis and androgen-secreting ovarian tumors, as some of these are gonadotropin-dependent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/22,24,25\">",
"       22,24,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ovarian venous sampling &mdash; When imaging studies are negative, but an ovarian source of androgens is still suspected, selective catheterization of the ovarian veins may be performed to demonstrate a left-to-right difference in androgen concentrations. However, this procedure should not be performed routinely as it is technically difficult and there is no consensus on the testosterone gradient that localizes the androgen source [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/26\">",
"       26",
"      </a>",
"      ]. It should only be performed by an experienced radiologist [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      We only suggest this procedure in premenopausal women interested in future fertility with serum T &gt;150",
"      <span class=\"nowrap\">",
"       ng/dL",
"      </span>",
"      (5.2",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      and a negative adrenal CT scan. In this instance, localization to one ovary would change management (eg, the patient would undergo a unilateral rather than a bilateral oophorectomy if a tumor source was located).",
"      <br/>",
"      <br/>",
"      In postmenopausal women, androgen-producing Leydig-cell tumors, many of which are located in the hilus (hilar cell tumors), may be found, but they are often too small to be seen on imaging studies. However, we do not suggest ovarian vein sampling in this setting because it is unlikely to change management (bilateral oophorectomy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H952682148\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;On histology, the ovary contains luteinized theca cells, which typically occur as single cell nests. Occasionally, nodules are scattered throughout the stroma (",
"    <a class=\"graphic graphic_picture graphicRef75548 \" href=\"mobipreview.htm?38/62/39909\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14632553\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian hyperthecosis should be suspected in women with a long-standing history of hirsutism, virilization, insulin resistance, and the hormonal pattern described above (see",
"    <a class=\"local\" href=\"#H952680715\">",
"     'Biochemical findings'",
"    </a>",
"    above). However, the diagnosis can be confirmed only by histologic examination of the ovaries and demonstration of the presence of nests of luteinized cells in the ovarian stroma. In practice, the definitive diagnosis is typically made by the pathologist after surgical removal of the ovary or a portion thereof (",
"    <a class=\"graphic graphic_picture graphicRef75548 \" href=\"mobipreview.htm?38/62/39909\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14632546\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14587957\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In postmenopausal women with severe hyperandrogenism, androgen-secreting ovarian and adrenal tumors, although rare, are the most important disorders to address in the differential diagnosis. Serum testosterone concentrations may be similar to those seen with ovarian hyperthecosis (eg, &gt;150",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [5.2",
"    <span class=\"nowrap\">",
"     nmol/L]),",
"    </span>",
"    but they are often considerably higher. Women with androgen-secreting tumors present with rapid onset and progression of hirsutism and virilization. Additional testing for diabetes is warranted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=see_link\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/22/12646?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Sertoli-stromal cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32916?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In premenopausal women, androgen-secreting ovarian and adrenal tumors must also be considered, but they are very rare. The approach to evaluating pre- or postmenopausal women with severe hyperandrogenemia, including testing for possible androgen-secreting tumors, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/31/9721?source=see_link&amp;anchor=H291833767#H291833767\">",
"     \"Evaluation of premenopausal women with hirsutism\", section on 'Additional evaluation for severe hyperandrogenemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common disorder in women that causes hirsutism is polycystic ovary syndrome (PCOS). Women with PCOS have lower serum testosterone concentrations, are not typically virilized, and are typically less insulin resistant when compared with women with hyperthecosis. In addition, the ultrasound appearance of the ovaries is different as described above. (See",
"    <a class=\"local\" href=\"#H952680508\">",
"     'Ultrasonography'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Polycystic ovary syndrome, as well as other disorders that cause hirsutism (such as idiopathic hirsutism and nonclassic 21-hydroxylase deficiency), are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/21/1367?source=see_link\">",
"     \"Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/51/35641?source=see_link\">",
"     \"Uncommon causes of congenital adrenal hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis of hyperandrogenism is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef83495 \" href=\"mobipreview.htm?16/56/17292\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The approach to evaluation of the patient with hirsutism is reviewed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/31/9721?source=see_link\">",
"     \"Evaluation of premenopausal women with hirsutism\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14632546\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of hyperthecosis should include therapy for hyperandrogenism (hirsutism and virilization), anovulation, obesity, and insulin resistance. The primary goal of treatment is to eliminate the excessive testosterone production.",
"   </p>",
"   <p>",
"    In postmenopausal women and in premenopausal women who completed childbearing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bilateral oophorectomy.",
"     </li>",
"     <li>",
"      Long-term GnRH-agonist treatment (with estrogen-progestin feedback) is an alternative, particularly in women who have an increased risk for surgery due to comorbidities or who are unwilling to undergo bilateral oophorectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/3,22,31,32\">",
"       3,22,31,32",
"      </a>",
"      ]. Androgen suppression is usually seen within six months of treatment and discontinuation of treatment can be considered after sustained normalization of testosterone levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/23\">",
"       23",
"      </a>",
"      ]. More clinical data are needed for precise recommendations on the duration of GnRH-agonist treatment. Since no histological diagnosis is available as final confirmation, it is recommended that all patients treated with GnRH-agonists receive careful follow-up, including periodic testing of androgen levels and ovarian imaging.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In premenopausal women:",
"   </p>",
"   <p>",
"    Treatment in premenopausal women is essentially the same as in women with the polycystic ovary syndrome (PCOS) (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1817?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adults\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It includes treatment of hirsutism mainly by local therapy, oral contraceptives, anti-androgens or GnRH-agonists combined with estrogen-progestin replacement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35416?source=see_link\">",
"       \"Treatment of hirsutism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For the treatment of anovulation and subsequent infertility in hyperthecosis,",
"      <strong>",
"      </strong>",
"      there is no evidence from clinical trials. First line treatment to induce ovulation should be",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      , although in a small series of women with hyperthecosis this was reported to be unsuccessful [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/13\">",
"       13",
"      </a>",
"      ]. In cases of clomiphene failure, gonadotropins can be used. As follicular development may be inhibited by the high intraovarian androgen concentrations, GnRH agonist pretreatment may reduce intraovarian androgen levels and result in restoration of sensitivity to exogenous gonadotropins with subsequent ovulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/31\">",
"       31",
"      </a>",
"      ].",
"      <br/>",
"     </li>",
"     <li>",
"      There are no published reports on the success of ovarian drilling in restoring ovulation, and procedures aiming at reducing ovarian stromal volume should be discouraged and considered as a last resort only.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional treatment recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obesity and insulin resistance &mdash; Weight reduction in obese women with hyperthecosis results in an increase in insulin sensitivity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38662/abstract/35\">",
"       35",
"      </a>",
"      ]. As a result, ovarian androgen secretion may decrease.",
"     </li>",
"     <li>",
"      Additionally, in women with type 2 diabetes or impaired glucose tolerance,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      treatment should be part of the treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1817?source=see_link\">",
"       \"Treatment of polycystic ovary syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14632538\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term hyperthecosis refers to the presence of nests of luteinized theca cells in the ovarian stroma due to differentiation of the ovarian interstitial cells into steroidogenically active luteinized stromal cells, causing hyperandrogenism with typical testosterone levels &gt;5.2",
"      <span class=\"nowrap\">",
"       nmol/L",
"      </span>",
"      (150",
"      <span class=\"nowrap\">",
"       ng/dL).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H952680715\">",
"       'Biochemical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A serum total testosterone concentration &lt;5.2",
"      <span class=\"nowrap\">",
"       nmol/L",
"      </span>",
"      (150",
"      <span class=\"nowrap\">",
"       ng/dL)",
"      </span>",
"      is likely to rule out hyperthecosis.",
"     </li>",
"     <li>",
"      Hyperthecosis must be differentiated from several other diseases, most importantly malignant androgen-producing ovarian or adrenal tumors, congenital adrenal hyperplasia (CAH), and Cushing&rsquo;s disease. Premenopausal women with PCOS have lower serum testosterone concentrations, are not typically virilized, and are typically less insulin resistant when compared with women with hyperthecosis. In addition, the ultrasound appearance of the ovaries is different. (See",
"      <a class=\"local\" href=\"#H14587957\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H952680508\">",
"       'Ultrasonography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Imaging of the ovaries (ultrasound and MRI if needed) and adrenals (by CT scan",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      MRI) is recommended to rule out testosterone-producing tumors. A single dose of long-acting GnRH-agonists can be used for diagnostic purposes to confirm the ovarian origin of androgens. (See",
"      <a class=\"local\" href=\"#H952680501\">",
"       'Imaging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H171735164\">",
"       'Additional testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of hyperthecosis depends on age, degree of virilization, and pregnancy goals. In postmenopausal women and premenopausal women who have completed childbearing, the main aim is to lower androgen levels by bilateral oophorectomy or long-term GnRH-agonist treatment. In premenopausal women, symptomatic treatment of hirsutism and ovulation induction for infertility may be indicated. Additional treatment should aim at reducing weight and insulin resistance. (See",
"      <a class=\"local\" href=\"#H14632546\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7765153\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and UpToDate would like to acknowledge Dr. Manubai Nagamani, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/1\">",
"      Goldman JM, Kapadia LJ. Virilization in a postmenopausal woman due to ovarian stromal hyperthecosis. Postgrad Med J 1991; 67:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/2\">",
"      Nagamani M, Hannigan EV, Dinh TV, Stuart CA. Hyperinsulinemia and stromal luteinization of the ovaries in postmenopausal women with endometrial cancer. J Clin Endocrinol Metab 1988; 67:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/3\">",
"      Barth JH, Jenkins M, Belchetz PE. Ovarian hyperthecosis, diabetes and hirsuties in post-menopausal women. Clin Endocrinol (Oxf) 1997; 46:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/4\">",
"      Geist, SH, Gains, JA. Diffuse luteinization of the ovaries associated with masculinization syndrome. Am J Obstet Gynecol 1942; 43:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/5\">",
"      Nagamani M, Van Dinh T, Kelver ME. Hyperinsulinemia in hyperthecosis of the ovaries. Am J Obstet Gynecol 1986; 154:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/6\">",
"      Krug E, Berga SL. Postmenopausal hyperthecosis: functional dysregulation of androgenesis in climacteric ovary. Obstet Gynecol 2002; 99:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/7\">",
"      RODDICK JW Jr, GREENE RR. Relation of ovarian stromal hyperplasia to endometrial carcinoma. Am J Obstet Gynecol 1957; 73:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/8\">",
"      Meldrum DR, Abraham GE. Peripheral and ovarian venous concentrations of various steroid hormones in virilizing ovarian tumors. Obstet Gynecol 1979; 53:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/9\">",
"      Friedman CI, Schmidt GE, Kim MH, Powell J. Serum testosterone concentrations in the evaluation of androgen-producing tumors. Am J Obstet Gynecol 1985; 153:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/10\">",
"      O'Driscoll JB, Mamtora H, Higginson J, et al. A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia. Clin Endocrinol (Oxf) 1994; 41:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/11\">",
"      Derksen J, Nagesser SK, Meinders AE, et al. Identification of virilizing adrenal tumors in hirsute women. N Engl J Med 1994; 331:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/12\">",
"      Nagamani M, Stuart CA. Specific binding sites for insulin-like growth factor I in the ovarian stroma of women with polycystic ovarian disease and stromal hyperthecosis. Am J Obstet Gynecol 1990; 163:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/13\">",
"      Nagamani M, Lingold JC, Gomez LG, Garza JR. Clinical and hormonal studies in hyperthecosis of the ovaries. Fertil Steril 1981; 36:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/14\">",
"      Rousset P, Gompel A, Christin-Maitre S, et al. Ovarian hyperthecosis on grayscale and color Doppler ultrasound. Ultrasound Obstet Gynecol 2008; 32:694.",
"     </a>",
"    </li>",
"    <li>",
"     Nagamani M, Chilvers R. Ultrasonography and diagnosis of polycystic ovary syndrome. In: Ultrasonography in Reproductive Medicine and Infertility, Rizk B.  (Ed), Cambridge University Press, New York 2010. p.75.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/16\">",
"      Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/17\">",
"      B&uuml;hler-Christen A, Tischler V, Diener PA, Br&auml;ndle M. New onset alopecia and hirsutism in a postmenopausal women. Gynecol Endocrinol 2009; 25:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/18\">",
"      Hall DA, McCarthy KA, Kopans DB. Sonographic visualization of the normal postmenopausal ovary. J Ultrasound Med 1986; 5:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/19\">",
"      Sherman ME, Lacey JV, Buys SS, et al. Ovarian volume: determinants and associations with cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2006; 15:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/20\">",
"      Rosenkrantz AB, Popiolek D, Bennett GL, Hecht EM. Magnetic resonance imaging appearance of ovarian stromal hyperplasia and ovarian hyperthecosis. J Comput Assist Tomogr 2009; 33:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/21\">",
"      Fujii S, Kiyokawa T, Tsukihara S, et al. Magnetic resonance imaging findings of ovarian stromal hyperthecosis. Acta Radiol 2009; 50:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/22\">",
"      Pascale MM, Pugeat M, Roberts M, et al. Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours. Clin Endocrinol (Oxf) 1994; 41:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/23\">",
"      Vollaard ES, van Beek AP, Verburg FA, et al. Gonadotropin-releasing hormone agonist treatment in postmenopausal women with hyperandrogenism of ovarian origin. J Clin Endocrinol Metab 2011; 96:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/24\">",
"      Chico A, Garc&iacute;a JL, Mat&iacute;as-Guiu X, et al. A gonadotrophin dependent stromal luteoma: a rare cause of post-menopausal virilization. Clin Endocrinol (Oxf) 1995; 43:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/25\">",
"      Pic&oacute;n MJ, Lara JI, Sarasa JL, et al. Use of a long-acting gonadotrophin-releasing hormone analogue in a postmenopausal woman with hyperandrogenism due to a hilus cell tumour. Eur J Endocrinol 2000; 142:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/26\">",
"      Kaltsas GA, Mukherjee JJ, Kola B, et al. Is ovarian and adrenal venous catheterization and sampling helpful in the investigation of hyperandrogenic women? Clin Endocrinol (Oxf) 2003; 59:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/27\">",
"      Petersons CJ, Burt MG. The utility of adrenal and ovarian venous sampling in the investigation of androgen-secreting tumours. Intern Med J 2011; 41:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/28\">",
"      Brown DL, Henrichsen TL, Clayton AC, et al. Ovarian stromal hyperthecosis: sonographic features and histologic associations. J Ultrasound Med 2009; 28:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/29\">",
"      Baldini M, Semprini E, Orsatti A, et al. Reduction of insulin resistance after correction of nonneoplastic ovarian virilization. J Endocrinol Invest 1993; 16:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/30\">",
"      Manieri C, Di Bisceglie C, Fornengo R, et al. Postmenopausal virilization in a woman with gonadotropin dependent ovarian hyperthecosis. J Endocrinol Invest 1998; 21:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/31\">",
"      Steingold KA, Judd HL, Nieberg RK, et al. Treatment of severe androgen excess due to ovarian hyperthecosis with a long-acting gonadotropin-releasing hormone agonist. Am J Obstet Gynecol 1986; 154:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/32\">",
"      Parr JH, Abraham RR, Seed M, et al. The treatment of a hyperandrogenic and virilizing state in an elderly female with a synthetic LHRH agonist. J Endocrinol Invest 1988; 11:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/33\">",
"      Luque-Ram&iacute;rez M, Alvarez-Blasco F, Botella-Carretero JI, et al. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92:2453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/34\">",
"      Sobbrio GA, Granata A, D'Arrigo F, et al. Treatment of hirsutism related to micropolycystic ovary syndrome (MPCO) with two low-dose oestrogen oral contraceptives: a comparative randomized evaluation. Acta Eur Fertil 1990; 21:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38662/abstract/35\">",
"      Kolterman OG, Insel J, Saekow M, Olefsky JM. Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects. J Clin Invest 1980; 65:1272.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7397 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-D60132E406-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_48_38662=[""].join("\n");
var outline_f37_48_38662=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14632538\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14632347\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H952680715\">",
"      Biochemical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H952680501\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H952680508\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H952680515\">",
"      - MRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H171735164\">",
"      - Additional testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H952682148\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14632553\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14587957\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14632546\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14632538\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7765153\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7397\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7397|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?25/28/26049\" title=\"diagnostic image 1\">",
"      Ovarian stroma ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7397|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/62/39909\" title=\"picture 1\">",
"      Ovarian hyperthecosis Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7397|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/56/17292\" title=\"table 1\">",
"      Differential diagnosis clinical hyperandrogenism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=related_link\">",
"      Clinical manifestations of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12826?source=related_link\">",
"      Clinical presentation and evaluation of adrenocortical tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/21/1367?source=related_link\">",
"      Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/36/39495?source=related_link\">",
"      Diagnosis of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/31/9721?source=related_link\">",
"      Evaluation of premenopausal women with hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28567?source=related_link\">",
"      Insulin resistance: Definition and clinical spectrum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/22/12646?source=related_link\">",
"      Sex cord-stromal tumors of the ovary: Sertoli-stromal cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32916?source=related_link\">",
"      Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35416?source=related_link\">",
"      Treatment of hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1817?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/51/35641?source=related_link\">",
"      Uncommon causes of congenital adrenal hyperplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_48_38663="Candesartan: Drug information";
var content_f37_48_38663=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Candesartan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/50/4902?source=see_link\">",
"    see \"Candesartan: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/61/21462?source=see_link\">",
"    see \"Candesartan: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atacand&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F144943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Candesartan&reg;;",
"     </li>",
"     <li>",
"      Atacand&reg;;",
"     </li>",
"     <li>",
"      CO Candesartan;",
"     </li>",
"     <li>",
"      JAMP-Candesartan;",
"     </li>",
"     <li>",
"      Mylan-Candesartan;",
"     </li>",
"     <li>",
"      PMS-Candesartan;",
"     </li>",
"     <li>",
"      Sandoz-Candesartan;",
"     </li>",
"     <li>",
"      Teva-Candesartan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F144977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin II Receptor Blocker;",
"     </li>",
"     <li>",
"      Antihypertensive",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F144946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Dosage must be individualized. Initial: 16 mg once daily; titrate to response (within 2 weeks, antihypertensive effect usually observed); usual range: 8-32 mg/day in 1-2 divided doses; maximum daily dose: 32 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heart failure:",
"     </b>",
"     Oral: Initial: 4 mg once daily; double the dose at 2-week intervals, as tolerated; target dose: 32 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     In selected cases, concurrent therapy with an ACE inhibitor may provide additional benefit.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13365164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/61/21462?source=see_link\">",
"      see \"Candesartan: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 1 to &lt;6 years: Initial: 0.2 mg/kg/day in 1-2 divided doses; titrate to response (within 2 weeks, antihypertensive effect usually observed); usual range: 0.05 to 0.4 mg/kg/day; maximum daily dose: 0.4 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6 to &lt;17 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;50 kg: Initial: 4-8 mg/day in 1-2 divided doses; titrate to response (within 2 weeks, antihypertensive effect usually observed); usual range: 2-16 mg/day; maximum daily dose: 32 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;50 kg: Initial: 8-16 mg/day in 1-2 divided doses; titrate to response (within 2 weeks, antihypertensive effect usually observed); usual range: 4-32 mg/day; maximum daily dose: 32 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F144947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. No initial dosage adjustment is necessary for elderly patients (although higher concentrations (C",
"     <sub>",
"      max",
"     </sub>",
"     ) and AUC were observed in these populations), for patients with mildly impaired renal function, or for patients with mildly impaired hepatic function.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13365165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 1 to &lt;17 years: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). Children with GFR &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     should not receive candesartan.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: No initial dosage adjustment necessary; however, in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ) AUC and C",
"     <sub>",
"      max",
"     </sub>",
"     were approximately doubled after repeated dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F144948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild impairment: No initial dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate impairment: Consider initiation at lower dosages (AUC increased by 145%).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as cilexetil:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atacand&reg;: 4 mg, 8 mg, 16 mg, 32 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13365166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F144921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alone or in combination with other antihypertensive agents in treating hypertension; treatment of heart failure (NYHA class II-IV)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Atacand&reg; may be confused with antacid",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F144975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, hypotension (heart failure 19%), MI, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, depression, dizziness, drowsiness, fever, headache, lightheadedness, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, hyperkalemia (heart failure &lt;1% to 6%), hypertriglyceridemia, hyperuricemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia, gastroenteritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, CPK increased, myalgia, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Serum creatinine increased (up to 13% in patients with heart failure with drug discontinuation required in 6%), hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, epistaxis, pharyngitis, rhinitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &lt;1%, postmarketing, and/or case reports: Abnormal hepatic function, agranulocytosis, anemia, hepatitis, hyponatremia, leukopenia, neutropenia, pruritus, renal failure, renal impairment, rhinitis, sinusitis, thrombocytopenia, urticaria; rhabdomyolysis has been reported (rarely) with angiotensin-receptor antagonists",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F144924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to candesartan or any component of the formulation; concomitant use with aliskiren in patients with diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F144908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: May occur; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium containing salts. Use cautiously, if at all, with these agents and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with candesartan.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic/mitral stenosis: Use caution in patients with significant aortic/mitral stenosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use caution when initiating in heart failure; may need to adjust dose, and/or concurrent diuretic therapy, because of candesartan-induced hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in patients with moderate hepatic impairment. Contraindicated in severe hepatic impairment and/or cholestasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use candesartan with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution with pre-existing renal insufficiency and severe renal impairment. Pediatric patients with a GFR &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     should not receive candesartan; has not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin-converting enzyme (ACE) inhibitors and renin inhibitors: Concomitant use of an ACE-inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children &lt;1 year of age must not receive candesartan; has not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anesthesia/surgery: Hypotension may occur during major surgery and anesthesia; use cautiously before, during, and immediately after such interventions.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F144970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (weak), CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F144938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Potassium supplements and/or potassium-containing salts may cause or worsen hyperkalemia. Management: Consult prescriber before consuming a potassium-rich diet, potassium supplements, or salt substitutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Dong quai has estrogenic activity. Ephedra, yohimbe, and ginseng may worsen hypertension. Garlic may increase antihypertensive effect of candesartan. Management: Avoid dong quai if using for hypertension. Avoid ephedra, yohimbe, ginseng, and garlic.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F144914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F144928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     The use of drugs which act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Use is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F144951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F144927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Atacand Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (30): $105.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (30): $105.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     16 mg (90): $317.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     32 mg (90): $429.58",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F144916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Supine blood pressure, electrolytes, serum creatinine, BUN, urinalysis, symptomatic hypotension, and tachycardia; in heart failure, serum potassium during dose escalation and periodically thereafter",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F144929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Amias (GB, IE);",
"     </li>",
"     <li>",
"      Anatan (KP);",
"     </li>",
"     <li>",
"      Atacand (AR, AT, AU, BB, BE, BF, BG, BJ, BM, BR, BS, BZ, CH, CI, CN, CO, CR, CZ, DE, DK, DO, EE, ES, ET, FI, FR, GH, GM, GN, GR, GT, HN, IE, IL, JM, KE, KP, LR, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, PA, PE, PL, PR, PT, RU, SC, SD, SE, SG, SL, SN, SV, TN, TR, TT, TZ, UG, UY, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Bilaten (CN);",
"     </li>",
"     <li>",
"      Blopress (AE, AT, BB, BH, BM, BR, BS, BZ, CH, CL, CR, CY, DE, DO, EC, EG, GT, GY, HK, HN, ID, IQ, IR, IT, JM, JO, JP, KW, LB, LY, MX, MY, NI, NL, OM, PA, PE, PH, PK, PR, QA, SA, SG, SR, SV, SY, TH, TT, TW, VE, YE);",
"     </li>",
"     <li>",
"      Blox (CN);",
"     </li>",
"     <li>",
"      Cancetil (KP);",
"     </li>",
"     <li>",
"      Candelotan (KP);",
"     </li>",
"     <li>",
"      Canderin (ID);",
"     </li>",
"     <li>",
"      Candesar (IN, KP);",
"     </li>",
"     <li>",
"      Candez (PH);",
"     </li>",
"     <li>",
"      Cansartan (KP);",
"     </li>",
"     <li>",
"      Cantar (IN);",
"     </li>",
"     <li>",
"      Desaltan (KP);",
"     </li>",
"     <li>",
"      Kenzen (FR);",
"     </li>",
"     <li>",
"      Minart (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Tiadyl (AR, PY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F144907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Candesartan is an angiotensin receptor antagonist. Angiotensin II acts as a vasoconstrictor. In addition to causing direct vasoconstriction, angiotensin II also stimulates the release of aldosterone. Once aldosterone is released, sodium as well as water are reabsorbed. The end result is an elevation in blood pressure. Candesartan binds to the AT1 angiotensin II receptor. This binding prevents angiotensin II from binding to the receptor thereby blocking the vasoconstriction and the aldosterone secreting effects of angiotensin II.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F144923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &gt;24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.13 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Parent compound bioactivated during absorption via ester hydrolysis within intestinal wall to candesartan",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination (dose dependent): 5-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (26%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):e1-e157.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636. Available at  file://www.circulationaha.org/cgi/content/full/110/5/588",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohn JN and Tognoni G, &ldquo;Valsartan Heart Failure Trial Investigators. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(23):1667-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/11759645/pubmed\" id=\"11759645\" target=\"_blank\">",
"        11759645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahlof B, Devereux RB, Kjeldsen SE, et al, &ldquo;Cardiovascular Morbidity and Mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9311):995-1003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/11937178/pubmed\" id=\"11937178\" target=\"_blank\">",
"        11937178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dickstein K and Kjekshus J, &ldquo;Effects of Losartan and Captopril on Mortality and Morbidity in High-Risk Patients After Acute Myocardial Infarction: The OPTIMAAL Randomised Trial. Optimal Trial in Myocardial Infarction With Angiotensin II Antagonist Losartan,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9335):752-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/12241832/pubmed\" id=\"12241832\" target=\"_blank\">",
"        12241832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Epstein BJ and Gums JG, &ldquo;Angiotensin Receptor Blockers Versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(3):470-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/15701766/pubmed\" id=\"15701766\" target=\"_blank\">",
"        15701766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Granger CB, McMurray JJ, Yusuf S, et al, &ldquo;Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Intolerant to Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Alternative Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):772-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/13678870/pubmed\" id=\"13678870\" target=\"_blank\">",
"        13678870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamroff G, Katz SD, Mancini D, et al, &ldquo;Addition of Angiotensin II Receptor Blockade to Maximal Angiotensin-Converting Enzyme Inhibition Improves Exercise Capacity in Patients With Severe Congestive Heart Failure,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(8):990-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/10051289/pubmed\" id=\"10051289\" target=\"_blank\">",
"        10051289",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 39(2 Suppl 2):1-246. Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McInnes GT, O'Kane KP, Jonker J, et al, &ldquo;The Efficacy and Tolerability of Candesartan Cilexetil in an Elderly Hypertensive Population,&rdquo;",
"      <i>",
"       J Hum Hypertens",
"      </i>",
"      , 1997, 11(Suppl 2):75-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/9140794/pubmed\" id=\"9140794\" target=\"_blank\">",
"        9140794",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McKelvie RS, Yusuf S, Pericak D, et al, &ldquo;Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study: The RESOLVD Pilot Study Investigators,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 100(10):1056-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/10477530/pubmed\" id=\"10477530\" target=\"_blank\">",
"        10477530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al, &ldquo;Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Taking Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Added Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):767-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/13678869/pubmed\" id=\"13678869\" target=\"_blank\">",
"        13678869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morsing P, Adler G, Brandt-Eliasson U, et al, &ldquo;Mechanistic Differences of Various AT1-Receptor Blockers in Isolated Vessels of Different Origin,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 1999, 33(6):1406-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/10373224/pubmed\" id=\"10373224\" target=\"_blank\">",
"        10373224",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, &ldquo;Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(2):203.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pitt B, Poole-Wilson PA, Segal R, et al, &ldquo;Effect of Losartan Compared With Captopril on Mortality in Patients With Symptomatic Heart Failure: Randomised Trial - The Losartan Heart Failure Survival Study ELITE II,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      ,  2000, 355(9215):1582-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/10821361/pubmed\" id=\"10821361\" target=\"_blank\">",
"        10821361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reif M, White WB, Fagan TC, et al, &ldquo;Effects of Candesartan Cilexetil in Patients With Systemic Hypertension. Candesartan Cilexetil Study Investigators,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1998, 82(8):961-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/9794352/pubmed\" id=\"9794352\" target=\"_blank\">",
"        9794352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Riegger GA, Bouzo H, Petr P, et al, &ldquo;Improvement in Exercise Tolerance and Symptoms of Congestive Heart Failure During Treatment With Candesartan Cilexetil,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 100(22):2224-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/10577995/pubmed\" id=\"10577995\" target=\"_blank\">",
"        10577995",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sipahi I, Debanne SM, Rowland DY, et al, &ldquo;Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(7):627-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/20542468/pubmed\" id=\"20542468\" target=\"_blank\">",
"        20542468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Swedberg K, Pfeffer M, Granger C, et al, &ldquo;Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM): Rationale and Design. Charm-Programme Investigators,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 1999, 5(3):276-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/10496201/pubmed\" id=\"10496201\" target=\"_blank\">",
"        10496201",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yusuf S, Pfeffer MA, Swedberg K, et al, &ldquo;Effects of Candesartan in Patients With Chronic Heart Failure and Preserved Left-Ventricular Ejection Fraction: The CHARM-Preserved Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):777-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/48/38663/abstract-text/13678871/pubmed\" id=\"13678871\" target=\"_blank\">",
"        13678871",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8670 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-481E12C6DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_48_38663=[""].join("\n");
var outline_f37_48_38663=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708657\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144942\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144943\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144977\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144946\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365164\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144947\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365165\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144948\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144918\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144904\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365166\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144921\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914574\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144975\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144924\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144908\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144970\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144913\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144938\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144914\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144928\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144951\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144927\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144916\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144929\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144907\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144923\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8670\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8670|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/50/4902?source=related_link\">",
"      Candesartan: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/61/21462?source=related_link\">",
"      Candesartan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_48_38664="Air embolism";
var content_f37_48_38664=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Air embolism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/48/38664/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/48/38664/contributors\">",
"     Liza C O'Dowd, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/48/38664/contributors\">",
"     Mark A Kelley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/48/38664/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/48/38664/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/48/38664/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/48/38664/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/48/38664/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Air embolism is an uncommon, but potentially catastrophic, event that occurs as a consequence of the entry of air into the vasculature. Venous air embolism (also called pulmonary air embolism) occurs when air enters the systemic venous circulation and travels to the right ventricle and pulmonary circulation. In contrast, arterial air embolism occurs when air enters the arterial system. Arterial air embolism can produce ischemia in any organ that has insufficient collateral circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The causes, pathophysiology, clinical features, diagnosis, treatment, and prognosis of air embolism are reviewed here. Embolization of thrombi, amniotic fluid, fat, or tumor is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4456?source=see_link\">",
"     \"Overview of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15016?source=see_link\">",
"     \"Amniotic fluid embolism syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25942?source=see_link\">",
"     \"Fat embolism syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23270?source=see_link\">",
"     \"Pulmonary tumor embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two conditions must exist for air embolism to occur. There must be direct communication between a source of air and the vasculature, and there must be a pressure gradient favoring the passage of air into the circulation rather than bleeding from the vessel. The clinical settings associated with air embolism are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef56802 \" href=\"mobipreview.htm?42/16/43275\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/1,2,5,6\">",
"     1,2,5,6",
"    </a>",
"    ]. They can be conceptualized as three general categories: surgery and trauma, intravascular catheterization, and barotrauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Surgery and trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous air embolism complicates neurosurgical and otolaryngological procedures more often than other types of surgical procedures. The major reason for this is that the surgical incision is usually superior to the heart at a distance that is greater than the central venous pressure. This sets up a condition of negative venous pressure relative to the atmosphere, which favors the passage of air into the circulation, especially when the patient is in a sitting position (ie, Fowler&rsquo;s position) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The estimated incidence of venous air embolism during neurosurgical procedures ranges from 10 percent (for surgical patients in the prone position) to 80 percent (for patients undergoing repair of cranial synostosis in Fowler's position) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/1,7,9-12\">",
"     1,7,9-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Venous air embolism has been reported following neodymium-yttrium-aluminum-garnet (Nd:YAG) laser treatment of endobronchial lesions, probably due to the coolant gas from the bronchoscope entering the systemic circulation through pulmonary venules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]. It has also been described during needle biopsy of the lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/14\">",
"     14",
"    </a>",
"    ], lung resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/15\">",
"     15",
"    </a>",
"    ], arthroscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/16\">",
"     16",
"    </a>",
"    ], total joint arthroplasty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/17\">",
"     17",
"    </a>",
"    ], hysteroscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/18-22\">",
"     18-22",
"    </a>",
"    ], laparoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/23\">",
"     23",
"    </a>",
"    ], cesarean section [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/24\">",
"     24",
"    </a>",
"    ], cardiopulmonary bypass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/25\">",
"     25",
"    </a>",
"    ], and various types of trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38645?source=see_link&amp;anchor=H5264479#H5264479\">",
"     \"Bronchoscopic laser resection\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/26/22951?source=see_link&amp;anchor=H14#H14\">",
"     \"Hysteroscopy: Managing fluid and gas distending media\", section on 'Gas embolism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/44/7882?source=see_link&amp;anchor=H9#H9\">",
"     \"Rare complications of ERCP\", section on 'Portal vein gas, air, and bile embolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Venous air embolism is not the only type of air embolism that occurs with trauma, however. Arterial air embolism has also been described following trauma (particularly head and neck injuries, penetrating or blunt chest trauma, and blunt abdominal trauma), which can be lethal. In a series of nine patients who were found to have air in their coronary arteries, left ventricle,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aortic root following penetrating chest trauma, six patients (66 percent) died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intravascular catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Air embolism is a serious and under-recognized complication related to intravascular catheters. It has been described with central venous catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/6,29-32\">",
"     6,29-32",
"    </a>",
"    ] (including those used for hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/33\">",
"     33",
"    </a>",
"    ]), pulmonary artery catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/34\">",
"     34",
"    </a>",
"    ], arterial catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], angioplasty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/37\">",
"     37",
"    </a>",
"    ], pacemaker placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/38\">",
"     38",
"    </a>",
"    ], defibrillator placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/38\">",
"     38",
"    </a>",
"    ], cardiac ablation procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/39\">",
"     39",
"    </a>",
"    ], and intravenous contrast injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Venous air emboli can occur at the time of catheter insertion, while the catheter is in place, or at the time of catheter removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/42\">",
"     42",
"    </a>",
"    ]. The risk of catheter-related venous air embolism appears to be increased by the following factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/2,6,32,42,43\">",
"     2,6,32,42,43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fracture or detachment of catheter connections (which accounts for 60 to 90 percent of episodes)",
"     </li>",
"     <li>",
"      Failure to occlude the needle hub",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      catheter during insertion or removal",
"     </li>",
"     <li>",
"      Dysfunction of self-sealing valves in plastic introducer sheaths",
"     </li>",
"     <li>",
"      Presence of a persistent catheter tract following the removal of a central venous catheter",
"     </li>",
"     <li>",
"      Deep inspiration during insertion or removal, which increases the magnitude of negative pressure within the thorax",
"     </li>",
"     <li>",
"      Hypovolemia, which reduces central venous pressure",
"     </li>",
"     <li>",
"      Upright positioning of the patient, which reduces central venous pressure to below atmospheric pressure and places the patient at particular risk for entraining air very rapidly into the venous circulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Barotrauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients requiring positive pressure ventilation are at risk for pulmonary barotrauma and, as a consequence, air emboli. Gas may enter the circulation if the pulmonary vascular integrity is disrupted concomitantly with alveolar rupture from overdistention of the airspaces. This complication has been reported most frequently in adults with the acute respiratory distress syndrome and in premature neonates with respiratory distress syndrome (hyaline membrane disease), but it can also occur in patients with other diagnoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/2,44-47\">",
"     2,44-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/10/32934?source=see_link\">",
"     \"Pulmonary barotrauma during mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Divers are also at risk for pulmonary barotrauma. A series estimated that pulmonary barotrauma and air embolism complicates approximately 7 of every 100,000 dives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/48\">",
"     48",
"    </a>",
"    ]. Rapid ascent without exhalation can result in expansion of gas in the lungs and consequent alveolar rupture. If the pulmonary veins tear as the alveoli rupture, air can return to the left heart with the oxygenated blood and then embolize through the arterial system to produce tissue ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Alternatively, air bubbles may form in the venous system during ascent and embolize to the systemic circulation via a patent foramen ovale [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4633?source=see_link\">",
"     \"Complications of scuba diving\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2824633\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts should be made to reduce the risk of air embolism. For patients who are mechanically ventilated, this means minimizing the airway pressures to prevent pulmonary barotrauma. For patients who require central venous catheterization, this means treating hypovolemia prior to catheter placement, occluding the hub of the central venous catheter during insertion, keeping all connections to a central line closed and locked when not in use, and placing the patient in the supine position and asking the patient to Valsalva or exhale during central venous catheter removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/1,10,32,52\">",
"     1,10,32,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/10/32934?source=see_link&amp;anchor=H10#H10\">",
"     \"Pulmonary barotrauma during mechanical ventilation\", section on 'Prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/1/29?source=see_link&amp;anchor=H15#H15\">",
"     \"Complications of central venous catheters and their prevention\", section on 'Venous air embolism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous air embolism is a consequence of air being introduced into the venous circulation, traveling to the right heart, and lodging in the pulmonary circulation. The effect of venous air embolization depends upon the rate and volume of air introduced into the venous circulation, since the capacity of the lung to filter microbubbles of air from the venous circulation can be exceeded. When this capacity is exceeded, air may pass through the pulmonary capillaries, enter the arterial circulation, and cause arterial air embolization with organ ischemia. It is estimated that 300 to 500 mL of gas introduced at a rate of 100",
"    <span class=\"nowrap\">",
"     mL/sec",
"    </span>",
"    is a fatal dose for humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/2,32\">",
"     2,32",
"    </a>",
"    ]. This flow rate can be attained through a 14-gauge catheter with a pressure gradient of only 5 cm H2O [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the incomplete filtration of venous air emboli by the pulmonary capillaries, arterial air embolism may be due to either the direct introduction of air into the arterial system or paradoxical embolization through a septal defect, patent foramen ovale, or pulmonary arterial-venous malformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/1\">",
"     1",
"    </a>",
"    ]. In patients with a left-to-right shunt, venous air embolization into the pulmonary circulation can raise right heart pressures and reverse the direction of the shunt, allowing paradoxical embolism to occur. Air in the arterial circulation can occlude the microcirculation and cause ischemic damage to end organs, such as the brain, spinal cord, heart, and skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/2,6,32\">",
"     2,6,32",
"    </a>",
"    ]. The organs may also be damaged secondarily by the release of inflammatory mediators and oxygen free radicals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/54\">",
"     54",
"    </a>",
"    ]. In addition to such end-organ sequelae, there may also be hemodynamic and pulmonary consequences from air embolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hemodynamic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gas introduced into the venous circulation can obstruct the pulmonary outflow tract, pulmonary arterioles,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary microcirculation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large bubbles tend to obstruct the pulmonary outflow tract (known as &ldquo;air lock\"). This diminishes blood flow from the right heart, resulting in increased central venous pressure, decreased pulmonary arterial pressure, and decreased systemic arterial pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Smaller bubbles tend to lodge within the pulmonary arterioles or pulmonary microcirculation, directly impeding blood flow and inducing vasoconstriction. As a result, the following hemodynamic effects may be observed: increased pulmonary vascular resistance, increased pulmonary arterial pressure, and increased right ventricular pressure. There may be an initial brief increase in the cardiac output and systemic arterial pressure due to tachycardia followed by a decrease in cardiac output and systemic arterial pressure, as well as myocardial ischemia due to hypoxia, right ventricular overload,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      air emboli to the coronary arterial circulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/1,10,32\">",
"       1,10,32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bubbles in the pulmonary microcirculation are associated with local endothelial damage and the accumulation of neutrophils, platelets, fibrin, and lipid droplets at the gas-fluid interface. Additional endothelial damage may be caused by the activation of complement and the release of mediators and free radicals from neutrophils and other inflammatory cells. Consequences of the endothelial damage may include noncardiogenic pulmonary edema, bronchoconstriction, and physiological changes, such as hypoxemia (due to alveolar flooding and ventilation-perfusion mismatching), increased physiologic dead space (with a rise in PaCO2 if ventilation is held constant), decreased lung compliance (secondary to pulmonary edema), and increased airway resistance (may be due to release of bronchoconstricting mediators such as serotonin and histamine from damaged endothelium) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/1,10,32,55-60\">",
"     1,10,32,55-60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor cases of air embolism are common and cause minimal or no symptoms. Severe cases are characterized by hemodynamic collapse",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acute insufficiency of certain organs, including the lungs, brain, and spinal cord. Dyspnea is almost a universal finding that may be accompanied by substernal chest pain, a sense of impending doom, lightheadedness, or dizziness. Signs of air embolism include a gasp or cough when the bolus of air enters the pulmonary circulation, a sucking noise as air is sucked into the intravascular space, a mill wheel murmur (a churning sound heard throughout the entire cardiac cycle), tachypnea, tachycardia, hypotension, wheezing, crackles, respiratory failure, a change in mental status, focal neurological deficits, crepitus over superficial vessels, livedo reticularis, and bubbles within retinal arteries (",
"    <a class=\"graphic graphic_table graphicRef76772 \" href=\"mobipreview.htm?20/14/20716\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/1,2,6,10,49\">",
"     1,2,6,10,49",
"    </a>",
"    ]. There may also be signs of acute right heart failure, such as an elevated jugular venous pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2823387\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Air embolism should be considered in any patient who has the sudden onset of cardiopulmonary or neurologic decompensation in a clinical setting that puts the patient at risk for air embolism (eg, central venous catheterization, neurosurgery) (",
"    <a class=\"graphic graphic_table graphicRef56802 \" href=\"mobipreview.htm?42/16/43275\">",
"     table 1",
"    </a>",
"    ). Disorders that should be considered in the differential diagnosis of such patients include all those that can cause acute pulmonary decompensation (pulmonary embolism, pneumothorax, bronchospasm, pulmonary edema), acute cardiovascular decompensation (hypovolemia, cardiogenic shock, myocardial infarction, septic shock, and electromechanical dissociation), or acute neurological decompensation (cerebral hypoperfusion, stroke, intraparenchymal or subarachnoid hemorrhage, hypoxic brain injury, head trauma, and metabolic disorders) (",
"    <a class=\"graphic graphic_table graphicRef67564 \" href=\"mobipreview.htm?27/62/28651\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2823395\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Air embolism is confirmed by the demonstration of air in the intravascular space, combined with an appropriate clinical setting. It is a difficult diagnosis to make because the air may be rapidly absorbed from the circulation, while the diagnostic tests are being arranged. Practically speaking, air embolism is often a diagnosis of exclusion, requiring the appropriate clinical setting and the exclusion of other life-threatening processes. The following diagnostic tests may provide supportive evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Electrocardiography",
"      </strong>",
"      &ndash; The electrocardiogram of patients with air embolism typically reveals sinus tachycardia, right heart strain (peaked p-waves), non-specific ST-segment and T-wave changes, and acute myocardial ischemia or infarction (",
"      <a class=\"graphic graphic_table graphicRef81655 \" href=\"mobipreview.htm?14/54/15212\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/1,2,32\">",
"       1,2,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Chest radiography",
"      </strong>",
"      &ndash; Patients with air embolism usually have a normal chest radiograph. A less common finding is pulmonary edema, while rare findings include air in the main pulmonary artery, focal oligemia, pulmonary artery enlargement, atelectasis, intracardiac air, and air in the hepatic circulation (",
"      <a class=\"graphic graphic_table graphicRef81655 \" href=\"mobipreview.htm?14/54/15212\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/1,2,32,61\">",
"       1,2,32,61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Arterial blood gases",
"      </strong>",
"      &ndash; Typical arterial blood gas abnormalities due to air embolism include hypoxemia and hypercarbia (",
"      <a class=\"graphic graphic_table graphicRef81655 \" href=\"mobipreview.htm?14/54/15212\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/1,2,32\">",
"       1,2,32",
"      </a>",
"      ]. The hypoxemia may be severe.",
"     </li>",
"     <li>",
"      <strong>",
"       Laboratory tests",
"      </strong>",
"      &ndash; Air embolism may be associated with a fall in the platelet count",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an elevation in the serum creatine kinase activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/1,2,32,62\">",
"       1,2,32,62",
"      </a>",
"      ]. In one study, 22 divers with arterial air embolism all had significant elevations in serum creatine kinase activity, whereas 22 divers without arterial air embolism did not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/62\">",
"       62",
"      </a>",
"      ]. The sensitivity of an elevated serum creatine kinase activity has not been studied in other populations with arterial air embolism.",
"     </li>",
"     <li>",
"      <strong>",
"       Echocardiography",
"      </strong>",
"      &ndash; Transthoracic and transesophageal echocardiography have been used to document the presence of air in the right ventricle. They may also show evidence of acute right ventricular dilation and pulmonary artery hypertension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/3,63\">",
"       3,63",
"      </a>",
"      ]. Continuous monitoring with echocardiography or transcranial Doppler has been used during high-risk surgical procedures to detect air embolism in the preclinical phase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/64-66\">",
"       64-66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       End-tidal CO2 monitoring",
"      </strong>",
"      &ndash; The increase in physiologic dead space and worsening of ventilation-perfusion matching that occur with venous air embolism produce a fall in end-tidal CO2. However, this finding is nonspecific and also occurs with pulmonary embolism, massive blood loss, circulatory arrest, or disconnection from the anesthesia circuit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/67\">",
"       67",
"      </a>",
"      ]. The combination of intraoperative echocardiography and end-tidal CO2 monitoring may increase the intraoperative sensitivity of detecting preclinical air emboli in high-risk patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/10,65\">",
"       10,65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Pulmonary artery catheterization",
"      </strong>",
"      &ndash; In patients who have a pulmonary artery catheter in position, a rise in the pulmonary artery pressure may be observed when venous air embolism occurs. However, this is a nonspecific finding, with an estimated sensitivity of only 45 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/65\">",
"       65",
"      </a>",
"      ]. Additional findings may include an increase in the central venous pressure, increase in the right ventricular pressure, decrease in the cardiac output, and decrease in the mean arterial pressure (",
"      <a class=\"graphic graphic_table graphicRef81655 \" href=\"mobipreview.htm?14/54/15212\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Ventilation-perfusion scan",
"      </strong>",
"      &ndash; Ventilation-perfusion scan abnormalities that mimic those seen in pulmonary thromboembolism may be seen in the setting of massive air embolism. However, perfusion defects due to air embolism resolve more rapidly, frequently within 24 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Computed tomography",
"      </strong>",
"      &ndash; Chest computed tomography (CT) may detect air emboli in the central venous system (especially the axillary and subclavian veins), right ventricle, or pulmonary artery. The specificity of these findings is greatest when large defects are detected because small (&lt;1 mL), asymptomatic air emboli are detectable in 10 to 25 percent of contrast-enhanced CT scans if carefully sought [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/40,69\">",
"       40,69",
"      </a>",
"      ]. False positive studies may be more common when higher resolution or electron beam CT scanners are used. Computed tomography of the brain may reveal intraparenchymal gas and diffuse edema (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57294 \" href=\"mobipreview.htm?43/23/44400\">",
"       image 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Pulmonary angiography",
"      </strong>",
"      &ndash; Pulmonary angiography may be normal in patients who have suffered air embolism, since the air may be rapidly resorbed between the onset of symptoms and the angiogram. Positive pulmonary angiography reveals vascular occlusion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      findings consistent with vasoconstriction. This includes corkscrewing, tapering, and delayed emptying of the vessels in the affected lung, compared to the unaffected lung [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care (eg, mechanical ventilation, vasopressors, volume resuscitation) is the cornerstone of managing a patient with air embolism. However, there are some interventions that can be used specifically for air embolism to prevent further embolization, restore circulation, and remove embolized air [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/1,2,32\">",
"     1,2,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2824273\">",
"    <span class=\"h2\">",
"     Prevention of further embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient with venous air embolization should be immediately placed into the left lateral decubitus position (Durant&rsquo;s maneuver), Trendelenburg position, or left lateral decubitus head down position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/4\">",
"     4",
"    </a>",
"    ]. These positions place the right ventricular outflow tract inferior to the right ventricular cavity, causing the air to migrate superiorly into a position within the right ventricle from which air is less likely to embolize [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/1,2,9,32\">",
"     1,2,9,32",
"    </a>",
"    ]. The potential benefit of appropriate positioning was suggested by an animal experiment in which 40 percent of animals in the left lateral decubitus position survived the venous injection of a lethal amount of air (the experiment did not assess the left lateral decubitus head down or Trendelenburg position) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, a patient with arterial air embolism should be placed in the flat supine position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/4\">",
"     4",
"    </a>",
"    ]. The reason that the optimal position differs for arterial and venous air embolism is that arterial blood flow is more forceful than venous blood flow and air bubbles are propelled forward by the arterial blood flow even if the patient is in a head down position. Since the head down positions described above are unlikely to trap air within the right ventricle and have the potential to exacerbate the cerebral edema that is typically induced by cerebral air embolism, a flat supine position is favored [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/4,72\">",
"     4,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2824289\">",
"    <span class=\"h2\">",
"     Restoration of the circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placing the patient in the left lateral decubitus, Trendelenburg, or left lateral decubitus head down position may also displace any large bubbles trapped in the right ventricular outflow track, causing them to migrate superiorly into a nonobstructing position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/1,2,9,32\">",
"     1,2,9,32",
"    </a>",
"    ]. If such positioning fails to restore circulation, closed-chest cardiac massage (ie, chest compressions) should be performed. The goal is to force air out of the pulmonary outflow tract and into smaller pulmonary vessels, improving forward blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/71,73\">",
"     71,73",
"    </a>",
"    ]. Closed-chest cardiac massage was as effective as either left lateral decubitus positioning or intracardiac aspiration of air in an animal study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2824335\">",
"    <span class=\"h2\">",
"     Removal of embolized air",
"    </span>",
"    &nbsp;&mdash;&nbsp;Air has been successfully aspirated from the right ventricle via a central venous catheter or percutaneously introduced needle, according to case reports and experimental models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/32,71\">",
"     32,71",
"    </a>",
"    ]. In general, however, these maneuvers are of limited benefit because the volume of air recovered is usually less than 20 mL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/65\">",
"     65",
"    </a>",
"    ]. Given the limited benefit, most clinicians only attempt to aspirate air if a central venous catheter is already in place [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/2,32\">",
"     2,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-flow supplemental oxygen (ie, a high fraction of inspired oxygen) increases the rate with which the embolized air resorbs. The supplemental oxygen increases the partial pressure of oxygen and decreases the partial pressure of nitrogen in blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/74\">",
"     74",
"    </a>",
"    ]. This produces a positive pressure gradient for the diffusion of nitrogen from the air bubbles to the blood, markedly accelerating bubble resorption. In contrast,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    (sometimes given during general anesthesia) can diffuse from blood to air emboli, causing the gas bubbles to enlarge and the patient to deteriorate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/75\">",
"     75",
"    </a>",
"    ]. Thus, nitrous oxide should be discontinued at the first suspicion of air embolism.",
"   </p>",
"   <p>",
"    Patients with evidence of cardiopulmonary compromise or neurologic deficits should receive hyperbaric oxygen therapy (HBO), if it is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/76-78\">",
"     76-78",
"    </a>",
"    ]. HBO reduces air bubble size and increases the arterial oxygen tension, potentially ameliorating ischemia. The potential clinical benefits of HBO were demonstrated by a retrospective cohort study of 86 patients with venous or arterial air embolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/79\">",
"     79",
"    </a>",
"    ]. Patients treated with HBO within six hours were more likely to recover than patients who received HBO six hours or later (68 versus 40 percent). Moreover, patients with a better outcome underwent HBO sooner than patients with a poor outcome (3.25 versus 4.75 hours). An important limitation to this study was its failure to adjust for severity of illness. While prompt initiation of HBO is preferred, it may improve outcome even if it is delayed up to 30 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/80\">",
"     80",
"    </a>",
"    ]. The potential benefits of HBO must be weighed against the potential risks of transport to the HBO facility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5448?source=see_link\">",
"     \"Hyperbaric oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial reports indicated that untreated patients with air embolism had a mortality rate in excess of 90 percent, although selective reporting of catastrophic cases may have biased these figures. A subsequent series from the 1960s reported a mortality rate of approximately 30 percent, likely reflecting the impact of interventions such as vasopressors, positioning, supplemental oxygen, and closed-chest cardiac massage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more recent series included 119 patients with either arterial or venous air embolism who were treated with HBO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38664/abstract/82\">",
"     82",
"    </a>",
"    ]. The series reported ICU, hospital, 6-month, and 1-year mortality rates of 12, 16, 18, and 21 percent, respectively. Risk factors for death in the ICU included cardiac arrest at the time of air embolization and a Simplified Acute Physiology II (SAPS II) score &ge;33 at ICU admission. Risk factors for death within one year included increasing age, the presence of a Babinski sign at ICU admission, and acute kidney failure. Among the survivors, 43 percent had neurological sequelae at the time of discharge from the ICU. These included visual field restriction (16 percent), persistent vegetative states (9 percent), focal motor deficits (7 percent), cognitive problems (7 percent), and seizures (4 percent). By six months, however, 75 percent of survivors had mild or no disability. Predictors of long-term neurological sequelae included focal motor deficits or a Babinski sign at ICU admission, as well as the need for more than five days of mechanical ventilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19807381\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Air embolism is an uncommon, but potentially catastrophic, event that occurs as a consequence of the entry of air into the vasculature. It can be venous or arterial. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Air embolism requires direct communication between a source of air and the vasculature, as well as a pressure gradient favoring the passage of air into the circulation. The clinical settings in which air embolism are most common include surgery, trauma, intravascular catheterization, and pulmonary barotrauma (",
"      <a class=\"graphic graphic_table graphicRef56802 \" href=\"mobipreview.htm?42/16/43275\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Venous air embolism is a consequence of air being introduced into the venous circulation. Arterial air emboli may be a consequence of incomplete filtration of venous air emboli by the pulmonary capillaries, the introduction of air directly into the arterial system, or paradoxical embolization. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Minor cases of air embolism are common and cause minimal or no symptoms. Severe cases are characterized by hemodynamic collapse",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      acute insufficiency of specific organs, including the lungs, brain, and spinal cord. Dyspnea is almost a universal finding (",
"      <a class=\"graphic graphic_table graphicRef76772 \" href=\"mobipreview.htm?20/14/20716\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Air embolism should be considered in any patient who has the sudden onset of cardiopulmonary or neurologic decompensation in a clinical setting that puts the patient at risk for air embolism. Disorders that should be considered in the differential diagnosis of such patients include all those that can cause acute pulmonary, cardiovascular, or neurological decompensation (",
"      <a class=\"graphic graphic_table graphicRef67564 \" href=\"mobipreview.htm?27/62/28651\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2823387\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Air embolism is confirmed by the demonstration of air in the intravascular space, combined with an appropriate clinical setting. It is a difficult diagnosis to make because the air may be rapidly absorbed from the circulation, while the diagnostic tests are being arranged. Practically speaking, air embolism is often a diagnosis of exclusion, requiring the appropriate clinical setting and the exclusion of other life-threatening processes. Several diagnostic tests may provide supportive evidence (",
"      <a class=\"graphic graphic_table graphicRef81655 \" href=\"mobipreview.htm?14/54/15212\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2823395\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supportive care (eg, mechanical ventilation, vasopressors, volume resuscitation) is the cornerstone of managing patients with air embolism. However, several other therapies may also be beneficial. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients with air embolism, we recommend the administration of supplemental oxygen with a high fraction of inspired oxygen (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2824335\">",
"       'Removal of embolized air'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with venous air embolism, we recommend placing the patient in the left lateral decubitus head down position, rather than leaving the patient supine (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The left lateral decubitus and Trendelenburg positions are acceptable alternative positions. (See",
"      <a class=\"local\" href=\"#H2824273\">",
"       'Prevention of further embolization'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Conversely, for patients with arterial air embolism, we recommend NOT placing the patient in a head down position (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2824273\">",
"       'Prevention of further embolization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients with air embolism and cardiac, pulmonary, or neurological deficits, we recommend hyperbaric oxygen (HBO) therapy if it is available within the medical center (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). HBO therapy should be initiated as soon as the patient is stable enough to go into the HBO chamber. For patients who are in a medical center that does not provide HBO therapy, the decision to transfer the patient to another medical center for HBO therapy must be made on a case-by-case basis, since there may be substantial risks associated with transferring a patient with air embolism. (See",
"      <a class=\"local\" href=\"#H2824335\">",
"       'Removal of embolized air'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The aspiration of air from the right ventricle using a preexisting central venous catheter and closed-chest cardiac massage (ie, chest compressions) are rescue therapies that may be attempted in patients who are severely hemodynamically unstable due to air embolism. (See",
"      <a class=\"local\" href=\"#H2824289\">",
"       'Restoration of the circulation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/1\">",
"      Dudney TM, Elliott CG. Pulmonary embolism from amniotic fluid, fat, and air. Prog Cardiovasc Dis 1994; 36:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/2\">",
"      King MB, Harmon KR. Unusual forms of pulmonary embolism. Clin Chest Med 1994; 15:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/3\">",
"      Muth CM, Shank ES. Gas embolism. N Engl J Med 2000; 342:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/4\">",
"      Jorens PG, Van Marck E, Snoeckx A, Parizel PM. Nonthrombotic pulmonary embolism. Eur Respir J 2009; 34:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/5\">",
"      Schmitt HJ, Hemmerling TM. Venous air emboli occur during release of positive end-expiratory pressure and repositioning after sitting position surgery. Anesth Analg 2002; 94:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/6\">",
"      Heckmann JG, Lang CJ, Kindler K, et al. Neurologic manifestations of cerebral air embolism as a complication of central venous catheterization. Crit Care Med 2000; 28:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/7\">",
"      Gale T, Leslie K. Anaesthesia for neurosurgery in the sitting position. J Clin Neurosci 2004; 11:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/8\">",
"      Wong AY, Irwin MG. Large venous air embolism in the sitting position despite monitoring with transoesophageal echocardiography. Anaesthesia 2005; 60:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/9\">",
"      Raskin JM, Benjamin E, Iberti TJ. Venous air embolism: case report and review. Mt Sinai J Med 1985; 52:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/10\">",
"      O'Quin RJ, Lakshminarayan S. Venous air embolism. Arch Intern Med 1982; 142:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/11\">",
"      Hybels RL. Venous air embolism in head and neck surgery. Laryngoscope 1980; 90:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/12\">",
"      Faberowski LW, Black S, Mickle JP. Incidence of venous air embolism during craniectomy for craniosynostosis repair. Anesthesiology 2000; 92:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/13\">",
"      Tellides G, Ugurlu BS, Kim RW, Hammond GL. Pathogenesis of systemic air embolism during bronchoscopic Nd:YAG laser operations. Ann Thorac Surg 1998; 65:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/14\">",
"      Horan TA, Pinheiro PM, Ara&uacute;jo LM, et al. Massive gas embolism during pulmonary nodule hook wire localization. Ann Thorac Surg 2002; 73:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/15\">",
"      Hemmerling TM, Schmidt J, Bosert C, Klein P. Systemic air embolism during wedge resection of the lung. Anesth Analg 2001; 93:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/16\">",
"      Peruto CM, Ciccotti MG, Cohen SB. Shoulder arthroscopy positioning: lateral decubitus versus beach chair. Arthroscopy 2009; 25:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/17\">",
"      Andersen KH. Air aspirated from the venous system during total hip replacement. Anaesthesia 1983; 38:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/18\">",
"      Guillard E, Nancy B, Floch H, et al. Intracerebral hemorrhage related to systemic gas embolism during hysteroscopy. Undersea Hyperb Med 2010; 37:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/19\">",
"      Sherlock S. Paradoxical gas embolism during hysteroscopy. Br J Anaesth 2008; 101:742; author reply 742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/20\">",
"      Groenman FA, Peters LW, Rademaker BM, Bakkum EA. Embolism of air and gas in hysteroscopic procedures: pathophysiology and implication for daily practice. J Minim Invasive Gynecol 2008; 15:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/21\">",
"      Grove JJ, Shinaman RC, Drover DR. Noncardiogenic pulmonary edema and venous air embolus as complications of operative hysteroscopy. J Clin Anesth 2004; 16:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/22\">",
"      Stoloff DR, Isenberg RA, Brill AI. Venous air and gas emboli in operative hysteroscopy. J Am Assoc Gynecol Laparosc 2001; 8:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/23\">",
"      Azevedo JL, Azevedo OC, Miyahira SA, et al. Injuries caused by Veress needle insertion for creation of pneumoperitoneum: a systematic literature review. Surg Endosc 2009; 23:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/24\">",
"      Cluver C, Novikova N, Hofmeyr GJ, Hall DR. Maternal position during caesarean section for preventing maternal and neonatal complications. Cochrane Database Syst Rev 2010; :CD007623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/25\">",
"      Schmitz ML, Faulkner SC, Johnson CE, et al. Cardiopulmonary bypass for adults with congenital heart disease: pitfalls for perfusionists. Perfusion 2006; 21:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/26\">",
"      Ho AM, Ling E. Systemic air embolism after lung trauma. Anesthesiology 1999; 90:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/27\">",
"      Platz E. Tangential gunshot wound to the chest causing venous air embolism: a case report and review. J Emerg Med 2011; 41:e25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/28\">",
"      Estrera AS, Pass LJ, Platt MR. Systemic arterial air embolism in penetrating lung injury. Ann Thorac Surg 1990; 50:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/29\">",
"      Laskey AL, Dyer C, Tobias JD. Venous air embolism during home infusion therapy. Pediatrics 2002; 109:E15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/30\">",
"      James PM Jr, Myers RT. Central venous pressure monitoring: misinterpretation, abuses, indications and a new technic. Ann Surg 1972; 175:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/31\">",
"      Doblar DD, Hinkle JC, Fay ML, Condon BF. Air embolism associated with pulmonary artery catheter introducer kit. Anesthesiology 1982; 56:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/32\">",
"      Orebaugh SL. Venous air embolism: clinical and experimental considerations. Crit Care Med 1992; 20:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/33\">",
"      Yu AS, Levy E. Paradoxical cerebral air embolism from a hemodialysis catheter. Am J Kidney Dis 1997; 29:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/34\">",
"      Jastremski MS, Chelluri L. Air embolism and cardiac arrest in a patient with a pulmonary artery catheter: a possible association. Resuscitation 1986; 14:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/35\">",
"      Chang C, Dughi J, Shitabata P, et al. Air embolism and the radial arterial line. Crit Care Med 1988; 16:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/36\">",
"      Lowenstein E, Little JW 3rd, Lo HH. Prevention of cerebral embolization from flushing radial-artery cannulas. N Engl J Med 1971; 285:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/37\">",
"      Leclercq F, Kassnasrallah S, Cesari JB, et al. Transcranial Doppler detection of cerebral microemboli during left heart catheterization. Cerebrovasc Dis 2001; 12:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/38\">",
"      Bongiorni MG, Di Cori A, Soldati E, et al. [Iatrogenic risk of permanent pacemaker and defibrillator implantation]. G Ital Cardiol (Rome) 2009; 10:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/39\">",
"      Hinkle DA, Raizen DM, McGarvey ML, Liu GT. Cerebral air embolism complicating cardiac ablation procedures. Neurology 2001; 56:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/40\">",
"      Woodring JH, Fried AM. Nonfatal venous air embolism after contrast-enhanced CT. Radiology 1988; 167:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/41\">",
"      Price DB, Nardi P, Teitcher J. Venous air embolization as a complication of pressure injection of contrast media: CT findings. J Comput Assist Tomogr 1987; 11:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/42\">",
"      Roberts S, Johnson M, Davies S. Near-fatal air embolism: fibrin sheath as the portal of air entry. South Med J 2003; 96:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/43\">",
"      Kashuk JL, Penn I. Air embolism after central venous catheterization. Surg Gynecol Obstet 1984; 159:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/44\">",
"      Morris WP, Butler BD, Tonnesen AS, Allen SJ. Continuous venous air embolism in patients receiving positive end-expiratory pressure. Am Rev Respir Dis 1993; 147:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/45\">",
"      Kane G, Hewins B, Grannis FW Jr. Massive air embolism in an adult following positive pressure ventilation. Chest 1988; 93:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/46\">",
"      Marini JJ, Culver BH. Systemic gas embolism complicating mechanical ventilation in the adult respiratory distress syndrome. Ann Intern Med 1989; 110:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/47\">",
"      Ulyatt DB, Judson JA, Trubuhovich RV, Galler LH. Cerebral arterial air embolism associated with coughing on a continuous positive airway pressure circuit. Crit Care Med 1991; 19:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/48\">",
"      Leitch DR, Green RD. Pulmonary barotrauma in divers and the treatment of cerebral arterial gas embolism. Aviat Space Environ Med 1986; 57:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/49\">",
"      Melamed Y, Shupak A, Bitterman H. Medical problems associated with underwater diving. N Engl J Med 1992; 326:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/50\">",
"      Wilmshurst P. Diving and oxygen. BMJ 1998; 317:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/51\">",
"      Schwerzmann M, Seiler C, Lipp E, et al. Relation between directly detected patent foramen ovale and ischemic brain lesions in sport divers. Ann Intern Med 2001; 134:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/52\">",
"      Pronovost PJ, Wu AW, Sexton JB. Acute decompensation after removing a central line: practical approaches to increasing safety in the intensive care unit. Ann Intern Med 2004; 140:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/53\">",
"      Ordway CB. Air embolus via CVP catheter without positive pressure: presentation of case and review. Ann Surg 1974; 179:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/54\">",
"      Dutka AJ, Kochanek PM, Hallenbeck JM. Influence of granulocytopenia on canine cerebral ischemia induced by air embolism. Stroke 1989; 20:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/55\">",
"      Warren BA, Philp RB, Inwood MJ. The ultrastructural morphology of air embolism: platelet adhesion to the interface and endothelial damage. Br J Exp Pathol 1973; 54:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/56\">",
"      Hartveit F, Lystad H, Minken A. The pathology of venous air embolism. Br J Exp Pathol 1968; 49:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/57\">",
"      Oyama Y, Spencer MP. Cardiopulmonary effects of intravenous gas embolism; with special reference to fate of intravascular gas bubbles. Jpn Circ J 1971; 35:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/58\">",
"      Adornato DC, Gildenberg PL, Ferrario CM, et al. Pathophysiology of intravenous air embolism in dogs. Anesthesiology 1978; 49:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/59\">",
"      Lam KK, Hutchinson RC, Gin T. Severe pulmonary oedema after venous air embolism. Can J Anaesth 1993; 40:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/60\">",
"      Clark MC, Flick MR. Permeability pulmonary edema caused by venous air embolism. Am Rev Respir Dis 1984; 129:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/61\">",
"      Kizer KW, Goodman PC. Radiographic manifestations of venous air embolism. Radiology 1982; 144:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/62\">",
"      Smith RM, Neuman TS. Elevation of serum creatine kinase in divers with arterial gas embolization. N Engl J Med 1994; 330:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/63\">",
"      Marcus RH, Weinert L, Neumann A, et al. Venous air embolism. Diagnosis by spontaneous right-sided contrast echocardiography. Chest 1991; 99:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/64\">",
"      Gottdiener JS, Papademetriou V, Notargiacomo A, et al. Incidence and cardiac effects of systemic venous air embolism. Echocardiographic evidence of arterial embolization via noncardiac shunt. Arch Intern Med 1988; 148:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/65\">",
"      Bedford RF, Marshall WK, Butler A, Welsh JE. Cardiac catheters for diagnosis and treatment of venous air embolism: a prospective study in man. J Neurosurg 1981; 55:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/66\">",
"      Markus H. Transcranial Doppler detection of circulating cerebral emboli. A review. Stroke 1993; 24:1246.",
"     </a>",
"    </li>",
"    <li>",
"     Sedlow DB, Irving SM. Monitoring and patient safety. In: Monitoring in Anesthesia and Critical Care Medicine, Blitt CD (Ed), Churchill Livingstone, New York 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/68\">",
"      Sessler CN, Kiser PE, Raval V. Transient pulmonary perfusion scintigraphic abnormalities in pulmonary air embolism. Chest 1989; 95:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/69\">",
"      Groell R, Schaffler GJ, Rienmueller R, Kern R. Vascular air embolism: location, frequency, and cause on electron-beam CT studies of the chest. Radiology 1997; 202:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/70\">",
"      Valentino R, Hilbert G, Vargas F, Gruson D. Computed tomographic scan of massive cerebral air embolism. Lancet 2003; 361:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/71\">",
"      Alvaran SB, Toung JK, Graff TE, Benson DW. Venous air embolism: comparative merits of external cardiac massage, intracardiac aspiration, and left lateral decubitus position. Anesth Analg 1978; 57:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/72\">",
"      Moon RE, de Lisle Dear G, Stolp BW. Treatment of decompression illness and latrogenic gas embolism. Respir Care Clin N Am 1999; 5:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/73\">",
"      ERICSSON JA, GOTTLIEB JD, SWEET RB. CLOSED-CHEST CARDIAC MASSAGE IN THE TREATMENT OF VENOUS AIR EMBOLISM. N Engl J Med 1964; 270:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/74\">",
"      Dexter F, Hindman BJ. Computer simulation of microscopic cerebral air emboli absorption during cardiac surgery. Undersea Hyperb Med 1998; 25:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/75\">",
"      Munson ES. Effect of nitrous oxide on the pulmonary circulation during venous air embolism. Anesth Analg 1971; 50:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/76\">",
"      Leach RM, Rees PJ, Wilmshurst P. Hyperbaric oxygen therapy. BMJ 1998; 317:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/77\">",
"      Closon M, Vivier E, Breynaert C, et al. Air embolism during an aircraft flight in a passenger with a pulmonary cyst: a favorable outcome with hyperbaric therapy. Anesthesiology 2004; 101:539.",
"     </a>",
"    </li>",
"    <li>",
"     The 7th European Consensus  Conference on Hyperbaric Medicine, Lille, France file://www.echm.org/ECHM-Conferences.htm (Accessed on August 03, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/79\">",
"      Blanc P, Boussuges A, Henriette K, et al. Iatrogenic cerebral air embolism: importance of an early hyperbaric oxygenation. Intensive Care Med 2002; 28:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/80\">",
"      Armon C, Deschamps C, Adkinson C, et al. Hyperbaric treatment of cerebral air embolism sustained during an open-heart surgical procedure. Mayo Clin Proc 1991; 66:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/81\">",
"      Murphy BP, Harford FJ, Cramer FS. Cerebral air embolism resulting from invasive medical procedures. Treatment with hyperbaric oxygen. Ann Surg 1985; 201:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38664/abstract/82\">",
"      Bessereau J, Genotelle N, Chabbaut C, et al. Long-term outcome of iatrogenic gas embolism. Intensive Care Med 2010; 36:1180.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8263 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-239B17CE44-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_48_38664=[""].join("\n");
var outline_f37_48_38664=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19807381\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Surgery and trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intravascular catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Barotrauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2824633\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hemodynamic complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2823387\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2823395\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2824273\">",
"      Prevention of further embolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2824289\">",
"      Restoration of the circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2824335\">",
"      Removal of embolized air",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19807381\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/8263\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8263|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?43/23/44400\" title=\"diagnostic image 1\">",
"      Massive cerebral air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8263|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/16/43275\" title=\"table 1\">",
"      Air embolism conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/14/20716\" title=\"table 2\">",
"      Air embolism clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/62/28651\" title=\"table 3\">",
"      Air embolism differential dx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/54/15212\" title=\"table 4\">",
"      Air embolism lab findings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/42/15016?source=related_link\">",
"      Amniotic fluid embolism syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/47/38645?source=related_link\">",
"      Bronchoscopic laser resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/1/29?source=related_link\">",
"      Complications of central venous catheters and their prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4633?source=related_link\">",
"      Complications of scuba diving",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25942?source=related_link\">",
"      Fat embolism syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5448?source=related_link\">",
"      Hyperbaric oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/26/22951?source=related_link\">",
"      Hysteroscopy: Managing fluid and gas distending media",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/10/32934?source=related_link\">",
"      Pulmonary barotrauma during mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23270?source=related_link\">",
"      Pulmonary tumor embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/44/7882?source=related_link\">",
"      Rare complications of ERCP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_48_38665="Disseminated superficial actinic porokeratosis - legs";
var content_f37_48_38665=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59742%7EDERM%2F81874%7EDERM%2F80248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59742%7EDERM%2F81874%7EDERM%2F80248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Disseminated superficial actinic porokeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous macules with peripheral keratotic rims are present on the lower legs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Disseminated superficial actinic porokeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple well-defined, erythematous macules with a peripheral rim of scale are present on the leg of this patient with disseminated superficial actinic porokeratosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Disseminated superficial actinic porokeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous macules with peripheral keratotic rims are present on the extremity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_48_38665=[""].join("\n");
var outline_f37_48_38665=null;
var title_f37_48_38666="Periprocedural complications of percutaneous coronary intervention";
var content_f37_48_38666=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Periprocedural complications of percutaneous coronary intervention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/48/38666/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/48/38666/contributors\">",
"     Joseph P Carrozza, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/48/38666/contributors\">",
"     Thomas Levin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/48/38666/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/48/38666/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/48/38666/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/48/38666/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/48/38666/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications seen during percutaneous coronary intervention (PCI) include those related to cardiac catheterization and diagnostic coronary angiography, and those that occur as a consequence of the specific equipment (eg, wires) required for the intervention or the intervention itself (eg, distal embolization leading to myocardial ischemia). The periprocedural complications related to PCI will be reviewed here. The complications of cardiac catheterization are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/42/42665?source=see_link\">",
"     \"Complications of diagnostic cardiac catheterization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Improvements in devices, the use of stents, and aggressive antiplatelet therapy have significantly reduced the incidence of major periprocedural complications of PCI over the past 15 to 20 years. As an example, the need for emergent coronary bypass surgery (CABG) decreased in two series from 1.5 percent in 1992 to 0.14 percent in 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/1\">",
"     1",
"    </a>",
"    ], and from 2.9 percent in 1979 to 1994 to 0.3 percent in 2000 to 2003 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Emergency CABG for failed PCI'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In this discussion, PCI refers to any therapeutic procedure during which a wire or catheter is inserted into a coronary artery. Balloon angioplasty without stenting will be referred to as PTCA. When clinically important data specific to PTCA is available, it will be given. The term PCI will be used when studies include patients who have had either PTCA or stenting. Studies of stenting alone will be presented as such.",
"   </p>",
"   <p>",
"    The widespread use of intracoronary stents rather than balloon angioplasty alone has resulted in the periprocedural complications of PTCA been being largely replaced by complications seen with stenting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREDICTORS OF MORTALITY AND MAJOR COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the present era, mortality rates for PTCA in large series from experienced operators ranged from 0.5 to 1.7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. In one review of PTCAs performed in 12,232 patients, procedural complications accounted for 54 percent of all post-PTCA deaths, while a preexisting acute cardiac condition accounted for 34 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/9\">",
"     9",
"    </a>",
"    ]. The most common mode of death was low output failure (66 percent); less common causes were ventricular arrhythmia, stroke, renal failure, bleeding, ventricular rupture, respiratory failure, pulmonary embolism, and infection.",
"   </p>",
"   <p>",
"    The widespread use of stents and improvements with time in stent design and technique have led to a decreasing risk of major acute complications and no increase in mortality rates despite the increasing complexity of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/3,10\">",
"     3,10",
"    </a>",
"    ]. A report from the American College of Cardiology National Cardiovascular Data registry included over 100,000 PCI procedures (stent placement in 77 percent) performed between 1998 and 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/10\">",
"     10",
"    </a>",
"    ]. The incidences of in-hospital Q wave MI, urgent CABG, or death were 0.4, 1.9, and 1.4 percent, respectively. These values probably represent an overestimate of current experience, as most laboratories report emergency CABG rates below 0.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/1,11\">",
"     1,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Influence of hospital and operator volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA/SCAI",
"    </span>",
"    guidelines for percutaneous coronary intervention made recommendations about hospital and operator volume and the importance of onsite cardiac surgery for both elective and primary PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/12\">",
"     12",
"    </a>",
"    ]. Hospitals should have a volume of at least 400 procedures per year, and operators should perform at least 75 procedures per year.",
"   </p>",
"   <p>",
"    The validity of the",
"    <span class=\"nowrap\">",
"     ACC/AHA/SCAI",
"    </span>",
"    guidelines in the era of coronary artery stenting has been demonstrated in a number of studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. The magnitude of this effect was illustrated in an analysis of a hospital discharge database that included over 360,000 admissions for PCI between 1998 and 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/13\">",
"     13",
"    </a>",
"    ]. Hospital volume was classified as low (5 to 199 cases per year), medium (200 to 399 cases per year), high (400 to 999 cases per year), and very high (over 1000 cases per year).",
"   </p>",
"   <p>",
"    Crude in-hospital mortality rates for the low-, medium-, high-, and very high-volume hospitals were 2.6, 1.8, 1.6, and 1.4 percent, respectively. After adjustment for clinical risk variables (including age, gender, race, acute MI, diabetes, and other factors), only low-volume hospitals had a significantly increased risk of in-hospital mortality (adjusted odds ratio 1.21).",
"   </p>",
"   <p>",
"    Worse outcomes in low-volume hospitals were also noted in a review of over 107,000 patients who underwent PCI in New York state between 1998 and 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/14\">",
"     14",
"    </a>",
"    ]. Only 2.3 percent of procedures were performed at hospitals with an annual volume below 400.",
"   </p>",
"   <p>",
"    A report from the greater Paris area registry suggested that the increase in in-hospital mortality in low volume centers was limited to emergency procedures (eg, primary PCI for ST elevation MI), with no difference in nonemergent procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/17\">",
"     17",
"    </a>",
"    ]. This probably reflects differential baseline risk of the patient populations, as mortality differences would be difficult to detect in very low-risk elective procedures.",
"   </p>",
"   <p>",
"    Operator volume is also a determinant of outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/14,18\">",
"     14,18",
"    </a>",
"    ]. The importance of operator volume was evaluated in a review from a regional consortium of 18,504 consecutive PCI&rsquo;s performed by 165 operators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/18\">",
"     18",
"    </a>",
"    ]. An inverse correlation was noted between major adverse cardiac events (MACE) occurring in-hospital and operator volume quintile. Patients treated by operators in the lowest two quintiles (1 to 33 and 34 to 89 cases per year) had, compared to those treated by operators in the highest quintile (207 to 582 cases per year), a significantly higher rate of MACE (7.4 and 6.1 compared to 4.2 percent, adjusted odds ratio 1.63 for both quintiles one and two), but not an increase in cardiac mortality.",
"   </p>",
"   <p>",
"    Similar findings were noted in the New York State review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/14\">",
"     14",
"    </a>",
"    ]. Procedures performed by operators with an annual volume of less than 75 cases were associated with a significant increase in the risk of same-day or same-stay CABG, but no significant difference in mortality. However, the risk of mortality was significantly increased when the hospital volume was below 400, and the operator volume was below 75 (2.7 versus 0.6 percent with both hospital and operator volumes above these thresholds, odds ratio 5.92).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Absence of on-site cardiac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;We and others believe it is reasonable to perform elective PCI at hospitals without on-site cardiac surgical services, as multiple studies have shown that outcomes are similar for stable patients undergoing PCI at hospitals with and without on-site cardiac surgical backup when measures of institutional and operator quality are evaluated (",
"    <a class=\"graphic graphic_table graphicRef68713 \" href=\"mobipreview.htm?33/37/34396\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80948 \" href=\"mobipreview.htm?34/42/35500\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef61364 \" href=\"mobipreview.htm?43/4/44107\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/19\">",
"     19",
"    </a>",
"    ]. The best evidence comes from a 2011 meta-analysis and two subsequent randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2011 meta-analysis of 11 studies that included over 900,000 patients found no increase in the average mortality rate (0.9 versus 0.8 percent, respectively; odds ratio [OR] 1.15, 95% CI 0.93-1.41) and no significant difference in the risk of emergency bypass surgery (OR 1.21, 95% CI 0.52-2.85) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The non-inferiority CPORT-E trial randomly assigned 18,867 patients with stable and unstable coronary disease in a 3:1 ratio to PCI at a hospital without or with on-site cardiac surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/21\">",
"       21",
"      </a>",
"      ]. Patients with ST-elevation MI, unprotected left main disease, or a left ventricular ejection fraction of less than 20 percent were excluded. There was no difference in the rates of the two co-primary outcomes at hospitals without or with cardiac surgery: mortality at six weeks (0.9 versus 1.0 percent, respectively; difference, -0.04 percentage points, 95% CI -0.31 to 0.23) or major adverse cardiac events at nine months (12.1 versus 11.2 percent, respectively; difference, 0.92 percentage points, 95% CI 0.04 to 1.80). However, the incidence of target vessel revascularization was significantly higher at non-SOS sites.",
"     </li>",
"     <li>",
"      The MASS COMM trial randomly assigned, in a 3:1 ratio, 3691 patients with indications for nonemergency PCI who presented at Massachusetts hospitals without on-site cardiac surgery to undergo PCI at that hospital or a hospital with cardiac surgery services [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/22\">",
"       22",
"      </a>",
"      ]. With regard to the co-primary composite end points of major adverse cardiac events (death, MI, repeat revascularization, or stroke) at 30 days (safety end point) and at 12 months (effectiveness end point), PCI procedures performed at hospitals without on-site cardiac surgery were noninferior (9.5 versus 9.4 percent; relative risk [RR] 1.00, 95% one-sided upper confidence limit, 1.22 and 17.3 versus 17.8 percent, RR 0.98, 95% one-sided upper confidence limit, 1.13).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2011 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Society",
"    </span>",
"    of Cardiovascular Angiography and Intervention guideline for PCI, written before the two randomized trials presented above, stated that elective PCI may be considered (weak recommendation) at institutions without on-site cardiac surgery that met certain institutional, operator, and patient selection criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The discussion of primary PCI at hospitals without on-site cardiac surgery is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link&amp;anchor=H17#H17\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'PCI without on-site cardiac surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lesion morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although clinical factors are thought to be of primary importance, lesion morphology also may be predictive. Furthermore, the clinical presentation and lesion complexity are often linked.",
"   </p>",
"   <p>",
"    In 1988, the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    published a classification of anatomic patterns that correlated with success and complication rates for PTCA. Lesions were divided into three categories, each representing a higher risk of complications and a lower rate of success (",
"    <a class=\"graphic graphic_table graphicRef80401 \" href=\"mobipreview.htm?26/35/27196\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type A lesions &mdash; high success and low restenosis rate.",
"     </li>",
"     <li>",
"      Type B lesions &mdash; intermediate success and moderate risk of restenosis. This has been further modified to type B1 (one adverse type B characteristic) and type B2 (more than one type B characteristic) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Type C lesions &mdash; low success and high risk of restenosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequent studies have also shown a correlation between lesion complexity and in-hospital outcome in the stent era:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review from the National Heart, Lung, and Blood Institute Dynamic Registry, complex lesions were defined as those with thrombus, calcification, bifurcation, ostial location, or chronic occlusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/26\">",
"       26",
"      </a>",
"      ]. Patients with complex lesions had significantly higher in-hospital rates of death, MI, or CABG.",
"     </li>",
"     <li>",
"      In an analysis from the TARGET trial, angiographic variables were evaluated for correlation with death, MI, or urgent target vessel revascularization at 30 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/27\">",
"       27",
"      </a>",
"      ]. Significant risk factors included thrombus, eccentricity, and lesion length &gt;20 mm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Short-term outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of multivariable risk models have been developed to predict in-hospital mortality and major complications after PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/28-40\">",
"     28-40",
"    </a>",
"    ]. Such models have typically been validated only within the institution at which they were developed, and some were based upon patient populations treated with balloon angioplasty alone.",
"   </p>",
"   <p>",
"    In one analysis, five of these multivariable mortality models were compared for their ability to predict in-hospital mortality in 4448 patients in the National Heart, Lung and Blood Institute Dynamic Registry who underwent PCI from 1997 to 1999 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/28\">",
"     28",
"    </a>",
"    ]. During the index hospitalization, 64 patients died (for an in-hospital mortality rate of 1.4 percent).",
"   </p>",
"   <p>",
"    This outcome was closely approximated by three of the models: the New York state model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], the Northern New England model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/32\">",
"     32",
"    </a>",
"    ], and the Cleveland Clinic model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/33\">",
"     33",
"    </a>",
"    ]. Two other models were less accurate: the University of Michigan model, which predicted 47 deaths (1.1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/34\">",
"     34",
"    </a>",
"    ], and the American College of Cardiology Registry model, which predicted 603 deaths (13.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Mayo Clinic developed a risk score to identify patients at increased risk for major complications after PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/36\">",
"     36",
"    </a>",
"    ]. The score, derived from patients who underwent PCI between 1996 and 1999 and then validated in 2000, is relevant to current clinical practice since it was performed after stenting became routine, the patients were usually treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    , and intravenous glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors were available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A predictive point score was based upon eight clinical and angiographic variables, including a number of high-risk parameters such as shock, heart failure, urgent or emergent PCI, and left main or multivessel disease (",
"    <a class=\"graphic graphic_table graphicRef54653 \" href=\"mobipreview.htm?22/36/23116\">",
"     table 5",
"    </a>",
"    ). Major complications were defined as in-hospital mortality, ST elevation MI, urgent or emergent CABG, and stroke. In the validation cohort, the observed complication rates were comparable to the expected rates for all risk levels. Since this risk model includes three angiographic variables, a low score derived from the five clinical variables would not permit exclusion of high risk prior to intervention.",
"   </p>",
"   <p>",
"    A subsequent study from the Mayo Clinic, using data from over 9000 PCI&rsquo;s performed between 2000 and 2005, developed two risk-prediction models, one for mortality alone and one for all major adverse cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/38\">",
"     38",
"    </a>",
"    ]. The model consisted of seven baseline clinical and noninvasive variables: age, MI within the past 24 hours, preprocedural shock, serum creatinine, left ventricular ejection fraction, heart failure, and peripheral artery disease. The two models successfully predicted the risk of adverse events during the index hospitalization. Limitations of the study include performance at a single, referral center in a lower-risk patient population.",
"   </p>",
"   <p>",
"    The risk models discussed above were derived from cohorts that included a high percentage of patients with a recent MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/39\">",
"     39",
"    </a>",
"    ]. Whether a preprocedural cardiac troponin (cTn) elevation in patients with stable coronary artery disease is a predictor of adverse postprocedural outcome was addressed using the EVENT registry of 7592 unselected patients undergoing PCI with stenting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/40\">",
"     40",
"    </a>",
"    ]. Of the 2382 stable EVENT patients, 142 (6 percent) were found to have baseline cTn above the upper limit of normal. Compared to patients with normal cTn, the following findings were noted at hospital discharge:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was a significantly higher rate of in-hospital death or MI (13.4 versus 5.6 percent). This was attributable in large part to an increase in periprocedural MI.",
"     </li>",
"     <li>",
"      In multivariable analyses baseline cTn elevation was an independent predictor of in-hospital death or MI (odds ratio, 2.1; 5% CI 1.2 to 3.8).",
"     </li>",
"     <li>",
"      There was a trend toward a higher rate of urgent repeat PCI (1.4 versus 0.2 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H536926950\">",
"    <span class=\"h3\">",
"     NCDR CathPCI risk score",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limitations to the adoption of widespread use of the above models include single-center enrollment (concern about generalizability), procedures performed before the routine use of drug-eluting stents or aggressive antithrombotic therapy, or focus on either acute coronary syndrome (ACS) or stable disease. The NCDR CathPCI risk score was developed and validated from an analysis of data from 181,775 procedures performed in the United States in a broad range of institutions from 2004 to 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/41\">",
"     41",
"    </a>",
"    ]. Patients were nearly evenly divided between those with ACS and those with stable disease. From an initial risk prediction model that included 21 variables, the eight with the strongest association with in-hospital mortality were included in the risk score: age, cardiogenic shock, prior heart failure, peripheral artery disease, chronic lung disease, glomerular filtration rate, New York Heart Association functional class IV, and PCI status (STEMI or no STEMI).",
"   </p>",
"   <p>",
"    In this population, overall in-hospital mortality following PCI was 1.27 percent, ranging from 0.65 to 4.81 percent in elective and ST-elevation myocardial infarction patients respectively. The risk score was very successful at predicting outcome (c-index 0.91).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mortality at one year",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial infarction after PCI predicts mortality at one year in patients who undergo PCI. A preprocedural elevation in cardiac troponin (cTn) also predicts adverse outcomes. In the EVENT registry discussed in the preceding section, a preprocedural elevation in cTn was associated with a two fold increase in the rate of death or MI at one year, including an increase in the rate of death from 0.4 to 2.4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39737?source=see_link\">",
"     \"Periprocedural myocardial infarction following percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The issue of whether either bleeding or urgent revascularization (both within 30 days) is also associated with late mortality was evaluated in an analysis of 5384 patients from four trials of patients referred for PCI who were pretreated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    and then randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/42\">",
"     42",
"    </a>",
"    ]. Mortality at one year was 3.6 percent in all patients and was significantly higher in those with either bleeding or urgent revascularization at 30 days (14.1 versus 3.3 and 15.4 versus 3.6 percent, respectively). Both major and minor bleeding were associated with late mortality.",
"   </p>",
"   <p>",
"    There is no definitive explanation for the association between bleeding and late mortality, but the analysis controlled for factors such as age, risk factors, left ventricular ejection fraction, creatinine level and presence of multivessel coronary artery disease. The presence of other potential confounders that may be associated with a sicker population cannot be excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CORONARY ARTERY COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of larger guiding catheters and sheaths makes damage to the proximal coronary artery more likely compared with diagnostic coronary arteriography. In addition, the advancement of guidewires and catheters into diseased coronary arteries may lead to vessel injury. Complications include coronary artery dissection, intramural hematoma, coronary artery perforation, and occlusion of branch vessels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dissection and abrupt closure after PTCA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major complications of PTCA, without intentional stenting, relate in large part to coronary arterial dissection and acute (abrupt) closure, which is most often due to arterial dissection. Some dissections result from overly vigorous attempts at guidewire passage, but most are due to the \"controlled injury\" induced by inflation of the dilation catheter. These problems are now much less frequent since stent placement is performed in most percutaneous coronary procedures.",
"   </p>",
"   <p>",
"    Dissections are found in up to 50 percent of patients immediately after PTCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/43\">",
"     43",
"    </a>",
"    ]. The occurrence of dissection cannot be predicted by preintervention analysis of lesion morphology or plaque composition by intracoronary ultrasound (IVUS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intimal tears or dissections following PTCA have been arbitrarily divided into types A to F [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type A &mdash; Luminal haziness",
"     </li>",
"     <li>",
"      Type B &mdash; Linear dissection",
"     </li>",
"     <li>",
"      Type C &mdash; Extraluminal contrast staining",
"     </li>",
"     <li>",
"      Type D &mdash; Spiral dissection",
"     </li>",
"     <li>",
"      Type E &mdash; Dissection with reduced flow",
"     </li>",
"     <li>",
"      Type F &mdash; Dissection with total occlusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Follow-up PTCA of mild dissections as early as six weeks after the procedure often demonstrates complete healing, although occasional late localized aneurysm formation has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/43,47,48\">",
"     43,47,48",
"    </a>",
"    ]. In contrast, larger dissections are associated with an increased risk of progression to total occlusion (abrupt closure) of the treated arterial segment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/47,49\">",
"     47,49",
"    </a>",
"    ]. In one series of 691 dissections following PTCA, 543 were type B; these patients had a course similar to those without dissections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/47\">",
"     47",
"    </a>",
"    ]. In comparison, patients with type C to F dissections had a high incidence of acute vessel closure (31 percent), MI (13 percent), and emergency CABG (37 percent).",
"   </p>",
"   <p>",
"    The increased risk of abrupt closure and MI associated with a large dissection has led to the routine use of stenting for any dissection. However, a stent may not be necessary for a nonocclusive dissection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. This was illustrated in a study that compared the outcome of 45 patients with 49 nonocclusive dissections (type A to D) and good distal flow (TIMI grade 3) who did not receive a stent with 60 patients with a dissection who underwent stenting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/50\">",
"     50",
"    </a>",
"    ]. At six months, there were no clinical adverse events in the unstented group, although the restenosis rate was lower than those who underwent stenting (12 versus 25 percent).",
"   </p>",
"   <p>",
"    Acute closure occurs in 4 to 9 percent of conventional balloon angioplasty cases and is associated with a 10-fold increase in mortality to about 1 percent and nonfatal MI (less than 5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/4,5,45-47,49,52\">",
"     4,5,45-47,49,52",
"    </a>",
"    ]. In certain subgroups &mdash; patients with extensive myocardial damage, multivessel disease, large territory at risk, or previous CABG &mdash; the consequences of acute closure can increase procedure-related mortality several fold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/49,53,54\">",
"     49,53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most cases of acute closure occur within minutes of the final balloon inflation, but subacute closure occurs up to hours later in 0.5 to 1.0 percent of cases, typically as the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    anticoagulation wears off [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/45,49\">",
"     45,49",
"    </a>",
"    ]. Stents can reverse abrupt closure in more than 90 percent of cases. However, some patients still require bypass surgery after stenting because of persistent coronary occlusion or dissection resulting in ischemia. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Emergency CABG for failed PCI'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Intramural hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery intramural hematoma is defined as an accumulation of blood within the medial space displacing the internal elastic membrane inward and the external elastic membrane outward, with or without identifiable entry and exit points. The following findings were noted in a study of 905 patients undergoing PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravascular ultrasound (IVUS) identified an intramural hematoma in 6.7 percent of procedures; the incidence was higher with angioplasty compared to stenting.",
"     </li>",
"     <li>",
"      The location was proximal to the lesion in 36 percent, confined to the lesion in 18 percent, and distal to the lesion in 46 percent.",
"     </li>",
"     <li>",
"      On angiography, the hematoma had the appearance of a dissection or a new lesion in 60 and 11 percent of cases; no significant abnormality was seen in 29 percent, in whom the diagnosis could only be made by IVUS.",
"     </li>",
"     <li>",
"      Patients with a hematoma had the same incidence of post-PCI non-ST elevation MI (NSTEMI) as those without a hematoma (26 percent), but a higher incidence of repeat revascularization within one month (6.3 versus 2 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perforation or frank rupture of coronary arteries, resulting from the guidewire, atherectomy devices, or balloons, occurs in 0.2 to 0.6 percent of patients undergoing PTCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/53,54,56,57\">",
"     53,54,56,57",
"    </a>",
"    ]. The incidence is higher with the use of atherectomy devices to ablate tissue for certain complex lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coronary artery perforation in the stent era is a rare but potentially catastrophic complication. In a series of over 10,000 PCI&rsquo;s (6836 with stenting) from 1993 to 2001, the risk of perforation was 0.84 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/58\">",
"     58",
"    </a>",
"    ]. Perforation occurred more often when an atheroablative device or intravascular ultrasound (IVUS) was used. However, perforation can also occur during stent placement, particularly when the stent is oversized and high deployment or postdilation pressures are used. Significant cardiac events occurred in 29 of 84 patients with a perforation (35 percent) and included MI in 15, repeat PCI in 4, CABG in 11, and death in 7.",
"   </p>",
"   <p>",
"    The degree of perforation varies from barely perceptible to severe and a classification scheme based upon angiographic appearance of the perforation has been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/57\">",
"     57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Class I - intramural crater without extravasation",
"     </li>",
"     <li>",
"      Class II - pericardial or myocardial blushing (staining)",
"     </li>",
"     <li>",
"      Class III - perforation &ge;1 mm in diameter with contrast streaming or cavity spilling",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of complications varies with the severity of the perforation. For class I, II, and III lesions, the respective values were 0, 14, and 50 percent for MI and 8, 13, and 63 percent for tamponade.",
"   </p>",
"   <p>",
"    Overall mortality with coronary perforation is about 5 to 10 percent, with the main risk factors being older age, tamponade, requirement for emergency surgery, and the severity of the perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In the above report of 62 patients, for example, deaths occurred only in patients with class III perforations (19 percent mortality) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The adjunctive use of the platelet glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptor antagonists during intervention does not increase the risk of adverse events in patients with a coronary perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/59\">",
"     59",
"    </a>",
"    ]. However, the use of newer hydrophilic guidewires in conjunction with aggressive antiplatelet therapy is anecdotally linked to an increased risk of distal wire perforation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H277378975\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious perforations require immediate treatment within the cath lab. The first measure is inflation of either a PTCA balloon or perfusion balloon catheter at the site of perforation to stop the flow of blood into the pericardium (giving time for pericardiocentesis, hemodynamic stabilization, and preparation of subsequent therapies), and may also be sufficient to seal off small perforations following a 15 minute inflation. If the perforation has not sealed, and evidence of hemodynamic compromise is seen (eg, hypotension), emergency pericardiocentesis with placement of a pericardial drain should be performed. Reversal of anticoagulation should occur only after access to the pericardial space is secured as blood in the pericardium may clot, making pericardiocentesis difficult.",
"   </p>",
"   <p>",
"    Significant distal perforations of small branches by guidewires can be managed by placement of embolization coils or other materials. This maneuver will result in total occlusion of that arterial segment.",
"   </p>",
"   <p>",
"    The covered stent, produced by attaching a polytetrafluoroethylene (PTFE) membrane to one stent or sandwiching such a layer between two stents, may be the stent of choice for treating coronary artery perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/60\">",
"     60",
"    </a>",
"    ]. One report evaluated 11 patients with a coronary rupture that was not treated successfully with prolonged balloon inflation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/61\">",
"     61",
"    </a>",
"    ]. Emergency insertion of a covered stent effectively sealed the perforation in all patients. Other patients who received a non-covered stent had a lower success rate and a higher incidence of tamponade and early surgery. During a 14 month follow-up, there were no major cardiac adverse events in the patients receiving a covered stent.",
"   </p>",
"   <p>",
"    These stents are available for treatment of perforations that cannot be managed by more conservative measures. The United States Food and Drug Administration has approved the Graftmaster PTFE-covered stent under a Humanitarian Device Exemption for the treatment of coronary perforation. When bleeding from the perforation site continues, emergent coronary bypass may be required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The indications for emergency surgery are continued bleeding or hemodynamic compromise unrelieved by pericardiocentesis. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Emergency CABG for failed PCI'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Distal embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Downstream embolization of thrombus or plaque contents (atheroma) with microvascular obstruction is common after PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/27\">",
"     27",
"    </a>",
"    ]. Slow antegrade flow from embolization is inversely correlated to CK-MB rise, supporting an association between microembolization and periprocedural necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39737?source=see_link\">",
"     \"Periprocedural myocardial infarction following percutaneous coronary intervention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=see_link&amp;anchor=H4#H4\">",
"     \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\", section on 'No-reflow phenomenon'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26538?source=see_link&amp;anchor=H25#H25\">",
"     \"Prevention, presentation, and management of saphenous vein graft stenosis\", section on 'Distal devices'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Side branch occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occlusion of side branches has been reported in up to 19 percent of cases in which a stent was placed across a major (&gt;1 mm) side branch (",
"    <a class=\"graphic graphic_figure graphicRef59539 \" href=\"mobipreview.htm?20/35/21054\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. In most cases, a greater than 50 percent stenosis has been present at the ostium of the side branch, and most occlusions occur after post-stent dilation performed with high-pressure inflations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/63\">",
"     63",
"    </a>",
"    ]. By six to nine months, all branches in these reports, including those previously occluded, were patent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. The low morbidity in these series may have reflected a tendency to avoid stent placement across large or diseased side branches.",
"   </p>",
"   <p>",
"    In a study of the mechanisms of myocardial injury after complex PCI, side branch occlusion at or adjacent to the site of stent placement was associated with myonecrosis in 12 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/66\">",
"     66",
"    </a>",
"    ]. In the TAXUS V study, overlapping",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    eluting stents had a higher incidence of periprocedural MI, possibly related to increased coverage of side branches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39737?source=see_link\">",
"     \"Periprocedural myocardial infarction following percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Stent jail",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stent coverage of a branch leaves the affected branch in \"stent jail\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. If needed, a guidewire can often be placed into this jailed branch and the ostium dilated through the stent struts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/68\">",
"     68",
"    </a>",
"    ]. This is possible with all of the new second generation stents, but many jailed side branches do not need further \"rescue\" maneuvers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Complications seen with stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improved stent design and technique have led to a decreasing risk of acute complications of PCI despite the increasing complexity of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/3,10\">",
"     3,10",
"    </a>",
"    ]. A report from the American College of Cardiology National Cardiovascular Data registry included over 100,000 PCI procedures (stenting in 77 percent) performed between 1998 and 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/10\">",
"     10",
"    </a>",
"    ]. The indication for PCI was an acute MI in 10 percent, while 52 percent had class II to IV chronic stable angina or unstable angina. The incidences of in-hospital Q wave MI, urgent CABG, or death were 0.4, 1.9, and 1.4 percent respectively. However, even these values represent an overestimate of current experience, as most laboratories report emergency CABG rates below 0.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two complications specific to stenting, failure of stent deployment and stent thrombosis, will be reviewed here. Complications of stenting that can also be seen with PTCA are discussed above. These include intramural hematoma, coronary artery perforation, distal embolization, and side branch occlusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Failure of stent deployment",
"    </span>",
"    &nbsp;&mdash;&nbsp;With first generation stents, failed deployment due to an inability to deliver the stent to or expand it within the target lesion occurred in 2.0 to as many as 8.3 percent of procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/5,70-72\">",
"     5,70-72",
"    </a>",
"    ]. Failed stent deployment with dislodgement from the delivery balloon is a potentially serious problem. In a series of 108 such cases, a serious in-hospital cardiac adverse event (urgent CABG, MI, or death) occurred in 19 percent and, by six months, 39 percent died, had an MI, or required repeat target lesion revascularization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/71\">",
"     71",
"    </a>",
"    ]. Stent retrieval was successful in 45 percent, but was associated with a high rate of complications: peripheral embolization in 38 percent and stent dislodgement into the left main coronary artery in 4 percent.",
"   </p>",
"   <p>",
"    The outcome of failed stent deployment is in part related to whether or not stent embolism is successfully managed. This was illustrated in a review of 387 patients with stent embolization, the incidence of at least one serious event (death, MI, or emergency bypass surgery) due to stent embolization within the coronary artery was 89 percent when the stent was not retrieved compared with 31 percent if the stent was successfully deployed at another site within the vessel and 9 percent when the stent was retrieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/73\">",
"     73",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of a serious event was 15 percent if the embolization occurred outside of the coronary artery, ie, within the aortic root.",
"     </li>",
"     <li>",
"      There were no cases of a serious ischemic event involving the kidneys or extremities, but one patient had a prolonged reversible ischemic neurologic event.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another series of 2894 procedures and 3815 lesions, a major cardiac event (cardiac death, MI, or repeat target vessel revascularization) occurred within 30 days in 43 percent of patients with unsuccessful attempted stent deployment, compared to 4 percent of those with successful deployment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/74\">",
"     74",
"    </a>",
"    ]. The risk of failure was higher for lesions of the left circumflex artery or saphenous vein grafts, after an acute occlusion before stenting, for longer and more complex stenoses, and for stenting of small vessels.",
"   </p>",
"   <p>",
"    Current second- and third-generation stents appear to have a higher rate of delivery success (&gt;98 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/74\">",
"     74",
"    </a>",
"    ], even in challenging anatomic situations, and are much less likely (&lt;0.5 percent) to strip off the delivery balloon during attempted placement or retrieval if the stent cannot cross the target lesion. In a large review, the incidence of stent loss with newer stents, which are premounted and have a low profile, ranged from 0.4 to 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Stent thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stent thrombosis is a potentially catastrophic complication that usually leads to death or MI. The patient often presents with symptoms and signs of acute MI, and the electrocardiogram may show ST segment elevation. This is a medical emergency and should be managed as such. The event can occur acutely (during or soon after the PCI), subacutely (within 30 days after stent placement), or as late as one year or more. Stent thrombosis has been associated with the cessation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    therapy. Acute or subacute thrombosis is linked to angiographic complications, such as residual dissection or slow flow. Very late stent thrombosis (ie, after one year) occurs more often with drug-eluting stents. These issues, including risk factors, prevention, and treatment, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Stent infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection of a coronary artery stent in a rare but potentially life threatening complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. It has been associated with formation of mycotic aneurysms and spontaneous coronary artery perforation. However, prophylactic antibiotics in the immediate post-procedure period or before dental or other procedures are not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MYOCARDIAL ISCHEMIA AND INFARCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Myocardial ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial ischemia can result from any of the coronary artery complications discussed above and can lead to variety of complications either during or after PCI, including chest pain, ST elevation MI (STEMI), cardiac enzyme elevation, and myocardial stunning.",
"   </p>",
"   <p>",
"    Patients may develop chest pain after coronary stenting for one of two reasons: ischemic chest pain (for which there is usually an apparent cause) and chest pain without an apparent cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/77\">",
"     77",
"    </a>",
"    ]. Chest pain without an apparent cause may be associated with a small cardiac enzyme elevation.",
"   </p>",
"   <p>",
"    Ischemic chest pain within 48 hours after stenting usually results from procedure-related events such as transient or persistent acute vessel closure (usually due to stent thrombosis or progression of an untreated dissection), transient coronary spasm, side branch occlusion of greater that 1.0 mm size, coronary dissection type C (as defined above), slow-flow or no flow, coronary perforation, prolonged hypotension, or distal embolization of atherosclerotic or thrombotic debris or air.",
"   </p>",
"   <p>",
"    In the EPISTENT trial, for example, ischemic chest pain after PCI occurred in 11 percent of patients, 12 percent of whom had associated ECG changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/78\">",
"     78",
"    </a>",
"    ]. When ECG changes were present, there was a significantly increased risk of a cardiac event (death, all MI, repeat revascularization) compared to an intermediate risk when chest pain without ECG changes was present and low risk in the absence of chest pain (42 versus 12 and 5 percent, respectively).",
"   </p>",
"   <p>",
"    Chest pain without an apparent cause is chest pain that is often atypical in quality and occurs within the first 24 hours after PCI in the absence of ECG changes or elevation in cardiac enzymes. It appears to occur more often after stenting compared to PTCA alone. Most patients describe the pain characteristics as being different from their typical angina (more localized and frequently pleuritic). This discomfort lasts for less than 72 hours in about 80 percent of patients, and less than two weeks in the remainder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This issue was addressed in an analysis of 1362 consecutive nonacute MI patients undergoing stenting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/77\">",
"     77",
"    </a>",
"    ]. After exclusion of 312 patients who were identified as having postprocedural chest pain and procedural events, 176 (13 percent) patients with postprocedural chest pain and no procedural events were compared to 874 patients without chest pain. Minor elevations in serum troponin I (56 versus 14 percent) and CK-MB (26 versus 10 percent) were found more often in the group with postprocedural chest pain suggesting that, even in patients with atypical chest pain and no ECG changes, myocardial ischemia may exist (subclinical micromyonecrosis). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39737?source=see_link\">",
"     \"Periprocedural myocardial infarction following percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the following observations were made in the patients with presumed nonischemic chest pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/77\">",
"     77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They had significant increase in postprocedural minimum lumen diameter (2.73 versus 2.45 mm), stent-to-vessel ratio, and inflation pressure (16 versus 13 mmHg) compared to patients without chest pain.",
"     </li>",
"     <li>",
"      Multivariate predictors of CK-MB elevation included a diagnosis of acute coronary syndrome, stent-to-vessel ratio &gt;1.1, inflation pressure &gt;16 atmospheres, thrombotic lesion, age, and",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      type C lesion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patients with presumed nonischemic chest pain also had more frequent cardiac events at follow-up:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At 30 days, a higher frequency of emergency room visits, readmissions, and repeat angiography (16 versus 3 percent) but no increase in repeat intervention, subacute thrombosis, death, or repeat MI.",
"     </li>",
"     <li>",
"      At six to nine months, a significantly higher rate of target vessel revascularization (30 versus 17 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;MI when defined as a rise in serum biomarker levels after PCI occurs frequently. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39737?source=see_link\">",
"     \"Periprocedural myocardial infarction following percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Emergency CABG for failed PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major indications for emergency CABG for patients who undergo PCI are hemodynamic compromise, ongoing ischemia or threatened occlusion (eg, acute vessel closure with PTCA alone) with significant myocardium at risk, and coronary rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/79\">",
"     79",
"    </a>",
"    ]. These complications may result from extensive dissection,",
"    <span class=\"nowrap\">",
"     perforation/tamponade,",
"    </span>",
"    or recurrent acute closure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients who have had an MI tend to require emergency CABG more often than those who have not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/1,7\">",
"     1,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common indication for emergency CABG in patients who undergo PCI with stenting is failed stent deployment, which is identified in the catheterization laboratory. Abrupt vessel closure and coronary artery dissection, which were the major causes of emergency CABG after PTCA alone, are less common with stenting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of emergency CABG after stenting is much lower than observed in the pre-stent era with PTCA alone. The magnitude of decline in emergency CABG can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of almost 19,000 PCI&rsquo;s performed at the Cleveland Clinic, the rate of emergency CABG fell from 1.5 percent in 1992 to 0.14 percent in 2000 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/1\">",
"       1",
"      </a>",
"      ]. This improvement was associated with marked increases in the use of coronary artery stents (5 to 81 percent), which were used significantly less often in the patients who required emergency CABG. From 1996 onward, emergency CABG was less likely in patients who received a stent.",
"     </li>",
"     <li>",
"      In a review of over 23,000 PCI&rsquo;s performed at the Mayo Clinic, the rate of emergency CABG fell from 2.9 percent in the pre-stent era (1979 to 1994) to 0.7 percent in the initial stent era (1995 to 1999) to 0.3 percent from 2000 to 2003 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/2\">",
"       2",
"      </a>",
"      ]. The improvement in outcome occurred despite an increase in high-risk patients requiring urgent or emergent PCI. In the last time period, there were fewer patients requiring CABG because of coronary artery dissection or abrupt vessel closure than in the pre-stent era.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The operative mortality in patients who required emergency CABG remained high and unchanged over time in these two series (10 to 15 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Acute MI and arrhythmia were the major causes of death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     VASCULAR COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular access site complications, such as bleeding and the need for surgical repair, occurring after PCI will be reviewed here. Similar complications occurring after diagnostic cardiac catheterization are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/42/42665?source=see_link&amp;anchor=H9#H9\">",
"     \"Complications of diagnostic cardiac catheterization\", section on 'Hemostasis at the access site'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The common femoral artery was the most frequent access site until about 2005, at which time many interventional cardiologists started preferring the radial artery for reasons presented below (see",
"    <a class=\"local\" href=\"#H59456800\">",
"     'Radial artery access'",
"    </a>",
"    below). The discussion here focuses principally on vascular complications using the common femoral artery.",
"   </p>",
"   <p>",
"    Vascular complications at the femoral artery access site, which occur in up to 6 percent of cases, make up a significant portion of the morbidity associated with PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. Minor or major hematomas and pseudoaneurysms are most common, followed by arterial laceration, retroperitoneal hematoma, arteriovenous fistula, arterial occlusion, and local infection with or without sepsis.",
"   </p>",
"   <p>",
"    Risk factors for vascular complications include periprocedural use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or fibrinolytic therapy, especially if there is prolonged or excessive anticoagulation, repeat procedure, atherectomy rather than PTCA; peripheral artery disease, advanced age, obesity, duration of time that the sheath remains in place, particularly if &gt;15 hours, use of intraaortic balloon pump, and, in some but not all series, larger arterial sheath size and cannulation of the superficial femoral artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/42/42665?source=see_link\">",
"     \"Complications of diagnostic cardiac catheterization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Access site bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Access site bleeding is in part related to anticoagulation and is more frequent when antiplatelet drugs are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. In the EPIC trial, for example, minor or major bleeding or surgery was significantly more common with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    compared to placebo (22 versus 9 percent), while the need for vascular surgery was equivalent (1.5 versus 1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women are at higher risk for bleeding and vascular complications compared with men; this difference is not fully explained by smaller vessel or body size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of bleeding requiring transfusion is also increased in elderly patients undergoing PCI, with a rate of 9 percent noted in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/86\">",
"     86",
"    </a>",
"    ]. This risk did not appear to be influenced by whether or not a glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor was given.",
"   </p>",
"   <p>",
"    Prevention of access site bleeding may be possible by reducing the intensity of anticoagulation, especially in patients receiving concomitant glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIa",
"    </span>",
"    inhibitors. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Anticoagulation-associated bleeding'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    is almost always used during PCI to reduce the risk of thrombosis, but continued therapy makes it more difficult to achieve hemostasis at the arterial access site. Some experts advocate that the dosing of unfractionated heparin during PCI should be guided by measurement of activated clotting times. Over-anticoagulation, especially with concomitant administration of glycoprotein",
"    <span class=\"nowrap\">",
"     2b/3a",
"    </span>",
"    receptor blockers is associated with higher risk of hemorrhage. The use of direct thrombin inhibitors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    rather than heparin and a glycoprotein",
"    <span class=\"nowrap\">",
"     2b/3a",
"    </span>",
"    receptor blocker is associated with lower risk of hemorrhagic complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/87-90\">",
"     87-90",
"    </a>",
"    ]. Postprocedural heparin is no longer recommended since the majority of abrupt closures occur immediately after the procedure, and the incidence of other ischemic events has decreased with the use of stents and antiplatelet agents given during or immediately after PCI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H19#H19\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Attaining hemostasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional approach to catheter removal at the conclusion of PCI was local hand-applied pressure for 15 to 30 minutes. Two alternative approaches are available: mechanical clamp compression and, more important, arterial puncture closing devices, which may increase the risk of complications. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/42/42665?source=see_link&amp;anchor=H9#H9\">",
"     \"Complications of diagnostic cardiac catheterization\", section on 'Hemostasis at the access site'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Retroperitoneal bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retroperitoneal bleeding represents a particularly serious type of preventable vascular complication. In our experience it is the most common cause of unexpected mortality after diagnostic or interventional cardiac catheterization. Retroperitoneal bleeding is frequently related to artery puncture that is above the inguinal ligament and can be prevented in most cases by careful attention to anatomic landmarks and fluoroscopy of the femoral head prior to needle puncture. Even with appropriate access position, back wall punctures that exit above the inguinal ligament may result in retroperitoneal bleeding and may not be sealed by manual compression or closure devices. Injudicious advancement of the guidewire or sheath by an inexperienced operator can also traumatize the iliac artery or the lateral circumflex artery and result in bleeding into the retroperitoneal space.",
"   </p>",
"   <p>",
"    The event is usually recognized by hemodynamic compromise. It can sometimes be mistaken for the more common and benign \"vagal\" reaction, since it may also present with profound bradycardia and associated hypotension. It is distinguished by only a transient response to initial volume loading and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Successful management depends on early recognition and volume resuscitation with crystalloid and blood. The diagnosis is usually confirmed by CT imaging. The vascular surgical team should be alerted, although surgical management is not commonly needed or helpful. We have used percutaneous methods including balloon inflation or placement of a covered stent to tamponade or seal the bleeding segment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59456800\">",
"    <span class=\"h2\">",
"     Radial artery access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheterization using the radial, as opposed to the common femoral, artery has the potential to reduce the risk of access site bleeding due to the fact that the former is readily compressible. Any intervention that reduces the risk of bleeding could potentially improve outcomes given the observations of increased mortality and ischemic events in patients who bleed at the time of PCI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40089?source=see_link\">",
"     \"Periprocedural bleeding in patients undergoing percutaneous coronary intervention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40089?source=see_link&amp;anchor=H13#H13\">",
"     \"Periprocedural bleeding in patients undergoing percutaneous coronary intervention\", section on 'Clinical outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early evidence of benefit (lower bleeding rates and improved survival) using radial artery catheterization came from observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/91\">",
"     91",
"    </a>",
"    ] and a 2009 meta-analysis that evaluated 23 small randomized trials (7020 patients) comparing radial with femoral access [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/92\">",
"     92",
"    </a>",
"    ]. In the meta-analysis, radial access significantly reduced the rate of major bleeding (0.5 versus 2.3 percent), and there was a trend for a reduction in the composite of death, MI, or stroke (2.5 versus 3.8 percent).",
"   </p>",
"   <p>",
"    The RIVAL trial, published in 2011, provides a more contemporary comparison of the two access strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/93\">",
"     93",
"    </a>",
"    ]. In RIVAL, 7021 patients with acute coronary syndromes were randomly assigned to either radial or femoral artery access. Patients were eligible if dual circulation of the hand was intact, as assessed by an Allen test. All interventional cardiologists had to have performed at least 50 radial procedures within the year prior to randomization (the average number of radial procedures in the prior year was 120). The primary outcome was a composite of death, MI, stroke, or non-coronary artery bypass graft related major bleeding. The following findings comparing radial to femoral access were noted at 30 days:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant difference in the rate of the primary outcome (3.7 versus 4.0 percent; hazard ratio [HR] 0.92, 95% CI 0.72-1.17). However, the primary outcome was significantly better with radial artery access in two prespecified subgroups:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients in the highest tertile volume radial centers (HR 0.49, 95% CI 0.28-0.87).",
"     </li>",
"     <li>",
"      Patients with ST-segment elevation MI (HR 0.60, 95% CI 0.38-0.94). This issue is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31721?source=see_link&amp;anchor=H1365622#H1365622\">",
"       \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management\", section on 'Technical issues'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of non-CABG related major bleeding was not significantly different (0.7 versus 0.9 percent).",
"     </li>",
"     <li>",
"      The rate of pseudoaneurysm requiring closure was significantly lower in the radial group (0.2 versus 0.6 percent).",
"     </li>",
"     <li>",
"      PCI success was 95 percent in both groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors of the RIVAL trial embedded an updated meta-analysis that included RIVAL and five additional trials into their publication. There were significantly lower rates of both non-CABG related major bleeding (0.5 versus 1.0 percent) and the composite of death, MI, or stroke (2.3 versus 3.5 percent) in patients who had their procedures performed in centers known for significant expertise with radial access. We and others believe the results of RIVAL are more compelling than the embedded meta-analysis, as the latter is comprised of trials that used older techniques (eg, larger guide catheters) and pharmacologic strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/94\">",
"     94",
"    </a>",
"    ]. The absence of a difference in bleeding in RIVAL may be explained by the low rate of femoral artery bleeding (compared to other trials). The authors hypothesize that this may be explained by a higher level of expertise among the RIVAL investigators compared to investigators in prior studies. Our experts make the following suggestions regarding the use of radial artery access catheterization and intervention:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that centers and individual operators develop expertise in use of the radial technique.&nbsp;",
"     </li>",
"     <li>",
"      Given the appreciable learning curve, we recommend that the technique be developed in elective cases before expanding to ST-elevation MI patients, for whom rapid restoration of flow remains the most important determinant of outcome.&nbsp;",
"     </li>",
"     <li>",
"      Continued mastery of the femoral artery access technique, including methods for reduction of postprocedure vascular complications, remains critical&nbsp;for cases where radial artery access is not preferred or when larger sheath size is needed for hemodynamic support and other complex cases.&nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Atheroembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of stiff, large-bore guiding catheters results in aortic trauma and the \"scraping\" of atheromatous debris from the aortic wall, providing a potential source of systemic embolism. In a series of 1000 patients undergoing PCI, 51 percent had aortic atheromatous material retrieved from the catheter after back flow of blood; the incidence ranged from 24 to 65 percent depending upon the shape of the catheter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/95\">",
"     95",
"    </a>",
"    ]. There were no associated in-hospital ischemic complications, probably due to sufficient withdrawal of blood containing the debris prior to the injection of contrast. Placement of a Y-adapter on the guiding catheter as the catheter is advanced over the guidewire should be discouraged, as this prevents backbleeding of atheromatous debris from the catheter.",
"   </p>",
"   <p>",
"    Atheroembolism related to cardiac catheterization and PCI is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/42/42665?source=see_link&amp;anchor=H28#H28\">",
"     \"Complications of diagnostic cardiac catheterization\", section on 'Atheroembolism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/15/31994?source=see_link\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     OTHER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Acute kidney injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute renal failure may occur after PCI. The most common causes are hemodynamic instability, radiocontrast toxicity, and atheroembolism. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/42/42665?source=see_link&amp;anchor=H29#H29\">",
"     \"Complications of diagnostic cardiac catheterization\", section on 'Acute renal failure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/13/13528?source=see_link\">",
"     \"Clinical presentation, evaluation, and treatment of renal atheroemboli\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stroke has been described as a complication of PCI in 0.07 to 0.4 percent of procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/96-98\">",
"     96-98",
"    </a>",
"    ]. Periprocedural stroke can occur from inadvertent wire passage into the cerebral vessels during catheter placement or from air or atherothrombotic debris released during catheter flushing. However, in most cases, it appears to occur in the setting of extensive atheroma in the aortic arch that are disrupted during guiding catheter advancement into the coronaries, a phenomenon that has been estimated to occur in over 50 percent of PCI&rsquo;s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/15/31994?source=see_link\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The largest series evaluated over 20,000 patients undergoing PCI, 37 percent with PTCA without stenting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/96\">",
"     96",
"    </a>",
"    ]. A stroke or transient ischemic attack (TIA) occurred in 92 patients (0.3 percent). Approximately half of the cerebrovascular events occurred in the anterior and half in the posterior cerebral circulation. Independent predictors of an event included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use of thrombolytic therapy or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      prior to PCI",
"     </li>",
"     <li>",
"      Urgent or emergent intervention",
"     </li>",
"     <li>",
"      Unplanned use of an intraaortic balloon pump",
"     </li>",
"     <li>",
"      Greater volume of radiocontrast used",
"     </li>",
"     <li>",
"      Previous history of hypertension, diabetes mellitus, or stroke",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with a cerebrovascular event had significantly higher rates of in-hospital mortality (25 versus 1.5 percent), acute renal failure (15 versus 1.6 percent), and new requirement for dialysis (4.4 versus 0.3 percent). The latter two findings suggest that atheroembolic events occurring in the cerebral circulation were often associated with similar events in the renal arteries.",
"   </p>",
"   <p>",
"    The more general issue of stroke and TIA related to cardiac catheterization is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/42/42665?source=see_link&amp;anchor=H5#H5\">",
"     \"Complications of diagnostic cardiac catheterization\", section on 'Stroke and transient ischemic attack'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relative risk of stroke, comparing PCI to coronary artery bypass graft surgery, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=see_link&amp;anchor=H3#H3\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\", section on 'CABG versus PCI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Anticoagulation-associated bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of antiplatelet and antithrombotic agents increases the risk of major periprocedural bleeding and the likelihood of a need for a transfusion of blood components, particularly when they are used in combination. The most common sites for bleeding requiring transfusion are the femoral access site as described above, the retroperitoneal space, and the gastrointestinal tract. Genitourinary tract bleeding is not uncommon, but usually does not require transfusion. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Access site bleeding'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors are often used during PCI because they reduce the frequency of ischemic complications, especially MI. In a large series, the risk of major and minor bleeding was greater with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    (16.7 versus 6.5 percent without abciximab) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/31/19961?source=see_link\">",
"     \"Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and low molecular weight heparin are associated with an increased risk of bleeding. The relative safety of these two agents in the setting of PCI is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H22#H22\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Low molecular weight heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of high doses of periprocedural",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    may be associated with gastrointestinal bleeding or hematuria. As an example, gross hematuria has been reported in up to 2 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/99\">",
"     99",
"    </a>",
"    ]. It should prompt a careful urologic evaluation since organic urinary tract disease, such as a urologic cancer, is a potential source [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/99\">",
"     99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The aggressive systemic anticoagulation used in the past led to the need for blood transfusions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vascular repair of the arterial vascular site in up to 14 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/82\">",
"     82",
"    </a>",
"    ]. However, the incidence of major bleeding complications has fallen with the appreciation that full stent deployment minimizes the need for systemic anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/100\">",
"     100",
"    </a>",
"    ]. In a controlled trial, for example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    were associated with fewer major bleeding episodes than a regimen of aspirin, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and phenprocoumon (0 versus 6.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the ACUITY and HORIZONS-AIM trials, use of monotherapy with the direct thrombin inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    was associated with lower risk of hemorrhage compared to the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (either unfractionated or low-molecular weight heparin) and a glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    receptor inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/89\">",
"     89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link&amp;anchor=H25#H25\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\", section on 'Bivalirudin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Drop in platelet count",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of, risk factors for, and prognostic implications of a drop in platelet count (DPC) were evaluated in a single center study of over 10,000 registry patients with baseline platelet counts",
"    <span class=\"nowrap\">",
"     &ge;100,000/microL",
"    </span>",
"    treated by PCI from 2000 to 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/102\">",
"     102",
"    </a>",
"    ]. Patients were divided into four strata: DPC &lt;10 percent; DPC 10 to 25 percent; DPC 25 to 50 percent; and DPC &ge;50 percent and DPC occurred in 36, 47.7, 14, and 2.3 percent of these strata respectively. Independent predictors of DPC &ge;25 percent included age, female sex, renal insufficiency, post-procedural renal failure, and use of an intra-aortic balloon pump. Potentially modifiable predictors of DPC included use of use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    as opposed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    , and use of low-osmolar contrast agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Ventricular arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular tachycardia (VT) and ventricular fibrillation (VF) appear to be uncommon after PCI, including primary PCI. A review of almost 20,000 PCI&rsquo;s performed at a single hospital, ventricular fibrillation (VF) occurred in 164 (0.8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/103\">",
"     103",
"    </a>",
"    ]. VF usually followed intracoronary contrast injection and all patients were successfully defibrillated in less than one minute with no sequelae.",
"   </p>",
"   <p>",
"    The frequency of these arrhythmias occurring in the cardiac catheterization laboratory at the time of planned primary PCI for ST elevation MI was analyzed in a review of 3065 patients from the PAMI trials, one-third of whom received a stent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/104\">",
"     104",
"    </a>",
"    ]. Ventricular arrhythmias occurred in 133 (4.3 percent). Variables independently associated with an increased risk of VT or VF included smoking, lack of preprocedural beta blockers, shorter time from symptom onset to emergency department arrival, initial TIMI flow grade 0, and right coronary artery-related infarct. Patients with VT or VF had higher rates of complications including cardiopulmonary resuscitation and intubation in the catheterization laboratory but had similar frequencies of major adverse cardiac events in-hospital and at one year.",
"   </p>",
"   <p>",
"    Ventricular arrhythmias occurring in the catheterization laboratory during primary PCI may be attributable to either the procedure, the myocardial infarction, or both. The discussion of ventricular arrhythmias in patients with ST elevation MI who are referred for PCI is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although PTCA is performed under sterile conditions, bacteremia and sepsis can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. In a review of over 4000 procedures, the incidence of bacteremia was 0.64 percent and the most common organisms were Staphylococcus aureus, coagulase-negative staphylococcus, and group B streptococcus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/105\">",
"     105",
"    </a>",
"    ]. Septic complications (femoral artery mycotic aneurysm, arthritis, and thrombosis) occurred in 0.24 percent. Risk factors for PTCA-related bacteremia were increased duration of the procedure, increased number of catheterizations at the same access site, difficult vascular access, and arterial sheath in place for more than one day. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37464?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/1/10263?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology of Staphylococcus aureus bacteremia in adults\", section on 'Prosthetic device'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Radiation exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing diagnostic and interventional cardiac catheterization receive substantial radiation exposure. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14376?source=see_link\">",
"     \"Radiation dose and risk of malignancy from cardiovascular imaging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Peripheral artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with peripheral artery disease (PAD) appear to be at an increased risk for periprocedural complications after PTCA. This was illustrated in a post hoc analysis from the BARI trial, which compared the outcome of 550 patients with PAD to that of 1770 patients without PAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/107\">",
"     107",
"    </a>",
"    ]. There were no differences in coronary anatomy or PTCA success rates between the two groups. However, patients with PAD had a higher incidence of a major complication (death, myocardial infarction, stroke, coma, or emergency revascularization) after PTCA (11.7 versus 7.8 percent for those without PAD), even after controlling for baseline differences.",
"   </p>",
"   <p>",
"    The trend for the use of smaller vascular sheaths (ie, 6F rather than 8F) and lower doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    may reduce the incidence of complications in this high-risk population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H329756925\">",
"    <span class=\"h1\">",
"     EARLY DISCHARGE IN LOW RISK PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the adverse outcomes noted above are seen within the first 48 hours after PCI. Some studies have suggested same day discharge is safe, particularly in low risk patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/108\">",
"     108",
"    </a>",
"    ]. The largest such study evaluated outcomes in over 107,000 patients undergoing elective PCI in the United States American College of Cardiology-National Cardiovascular Disease Registry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/109\">",
"     109",
"    </a>",
"    ]. After adjustment for patient and procedure characteristics, same-day discharge was not significantly associated with an increased risk of death or hospitalization at 30 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168227244\">",
"    <span class=\"h1\">",
"     READMISSION WITHIN 30 DAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Readmission rates at 30 days after PCI as high as 15 percent have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/110\">",
"     110",
"    </a>",
"    ]. In a single center study of over 15,000 patients who underwent (both urgent and non-urgent) PCI between 1998 and 2008, the 30-day rate was 9.4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/48/38666/abstract/111\">",
"     111",
"    </a>",
"    ]. After multivariable analysis, the following factors (none of which is modifiable) were associated with an increased risk of readmission: female sex, Medicare insurance, having less than a high school education, unstable angina, cerebrovascular accident or transient ischemic attack, moderate to severe renal disease, chronic obstructive pulmonary disease, peptic ulcer disease, metastatic cancer, and a length of stay of more than three days. Readmission was associated with a higher risk of one-year mortality (adjusted hazard ratio, 1.38, 95% CI 1.08-1.75).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/38/18020?source=see_link\">",
"       \"Patient information: Heart stents and angioplasty (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90372493\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aside from comorbidities, important predictors of adverse short-term outcomes in the periprocedural period include: lower hospital or operator volume; absence of on-site cardiac surgery; lesion complexity. Risk scores are available to predict adverse outcomes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Predictors of mortality and major complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mortality at one year is predicted by periprocedural myocardial infarction and bleeding. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Mortality at one year'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important complications include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In-hospital death, which occurs at a rate around one percent. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Short-term outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coronary artery complications such as perforation, distal embolization, side branch occlusion, or stent thrombosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Coronary artery complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myocardial ischemia and infarction. Occasionally, this may require urgent coronary artery bypass graft surgery. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Myocardial ischemia and infarction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vascular complications including access site and retroperitoneal bleeding or atheroembolism. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Vascular complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stroke, which occurs at a rate of about one to four per thousand. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Stroke'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other important complications include acute kidney injury and anticoagulation-associated bleeding. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Other'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26121304\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to thank Dr. David O. Williams for his contributions as a Section Editor to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/1\">",
"      Seshadri N, Whitlow PL, Acharya N, et al. Emergency coronary artery bypass surgery in the contemporary percutaneous coronary intervention era. Circulation 2002; 106:2346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/2\">",
"      Yang EH, Gumina RJ, Lennon RJ, et al. Emergency coronary artery bypass surgery for percutaneous coronary interventions: changes in the incidence, clinical characteristics, and indications from 1979 to 2003. J Am Coll Cardiol 2005; 46:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/3\">",
"      Weintraub WS, Mahoney EM, Ghazzal ZM, et al. Trends in outcome and costs of coronary intervention in the 1990s. Am J Cardiol 2001; 88:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/4\">",
"      Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/5\">",
"      Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/6\">",
"      Topol EJ, Leya F, Pinkerton CA, et al. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group. N Engl J Med 1993; 329:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/7\">",
"      Maynard C, Chapko MK, Every NR, et al. Coronary angioplasty outcomes in the Healthcare Cost and Utilization Project, 1993-1994. Am J Cardiol 1998; 81:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/8\">",
"      Dorros G, Cowley MJ, Simpson J, et al. Percutaneous transluminal coronary angioplasty: report of complications from the National Heart, Lung, and Blood Institute PTCA Registry. Circulation 1983; 67:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/9\">",
"      Malenka DJ, O'Rourke D, Miller MA, et al. Cause of in-hospital death in 12,232 consecutive patients undergoing percutaneous transluminal coronary angioplasty. The Northern New England Cardiovascular Disease Study Group. Am Heart J 1999; 137:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/10\">",
"      Anderson HV, Shaw RE, Brindis RG, et al. A contemporary overview of percutaneous coronary interventions. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). J Am Coll Cardiol 2002; 39:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/11\">",
"      Kutcher MA, Klein LW, Ou FS, et al. Percutaneous coronary interventions in facilities without cardiac surgery on site: a report from the National Cardiovascular Data Registry (NCDR). J Am Coll Cardiol 2009; 54:16.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (accessed September 18, 2007) www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/13\">",
"      Epstein AJ, Rathore SS, Volpp KG, Krumholz HM. Hospital percutaneous coronary intervention volume and patient mortality, 1998 to 2000: does the evidence support current procedure volume minimums? J Am Coll Cardiol 2004; 43:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/14\">",
"      Hannan EL, Wu C, Walford G, et al. Volume-outcome relationships for percutaneous coronary interventions in the stent era. Circulation 2005; 112:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/15\">",
"      Wennberg DE, Lucas FL, Siewers AE, et al. Outcomes of percutaneous coronary interventions performed at centers without and with onsite coronary artery bypass graft surgery. JAMA 2004; 292:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/16\">",
"      Malenka DJ, McGrath PD, Wennberg DE, et al. The relationship between operator volume and outcomes after percutaneous coronary interventions in high volume hospitals in 1994-1996: the northern New England experience. Northern New England Cardiovascular Disease Study Group. J Am Coll Cardiol 1999; 34:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/17\">",
"      Spaulding C, Morice MC, Lancelin B, et al. Is the volume-outcome relation still an issue in the era of PCI with systematic stenting? Results of the greater Paris area PCI registry. Eur Heart J 2006; 27:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/18\">",
"      Moscucci M, Share D, Smith D, et al. Relationship between operator volume and adverse outcome in contemporary percutaneous coronary intervention practice: an analysis of a quality-controlled multicenter percutaneous coronary intervention clinical database. J Am Coll Cardiol 2005; 46:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/19\">",
"      Shahian DM, Meyer GS, Yeh RW, et al. Percutaneous coronary interventions without on-site cardiac surgical backup. N Engl J Med 2012; 366:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/20\">",
"      Singh M, Holmes DR Jr, Dehmer GJ, et al. Percutaneous coronary intervention at centers with and without on-site surgery: a meta-analysis. JAMA 2011; 306:2487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/21\">",
"      Aversano T, Lemmon CC, Liu L, Atlantic CPORT Investigators. Outcomes of PCI at hospitals with or without on-site cardiac surgery. N Engl J Med 2012; 366:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/22\">",
"      Jacobs AK, Normand SL, Massaro JM, et al. Nonemergency PCI at Hospitals with or without On-Site Cardiac Surgery. N Engl J Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/23\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:2574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/24\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:e574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/25\">",
"      Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990; 82:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/26\">",
"      Wilensky RL, Selzer F, Johnston J, et al. Relation of percutaneous coronary intervention of complex lesions to clinical outcomes (from the NHLBI Dynamic Registry). Am J Cardiol 2002; 90:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/27\">",
"      Ross MJ, Herrmann HC, Moliterno DJ, et al. Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial. J Am Coll Cardiol 2003; 42:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/28\">",
"      Holmes DR, Selzer F, Johnston JM, et al. Modeling and risk prediction in the current era of interventional cardiology: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. Circulation 2003; 107:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/29\">",
"      Shaw RE, Anderson HV, Brindis RG, et al. Development of a risk adjustment mortality model using the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR) experience: 1998-2000. J Am Coll Cardiol 2002; 39:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/30\">",
"      Hannan EL, Racz M, Ryan TJ, et al. Coronary angioplasty volume-outcome relationships for hospitals and cardiologists. JAMA 1997; 277:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/31\">",
"      Hannan EL, Arani DT, Johnson LW, et al. Percutaneous transluminal coronary angioplasty in New York State. Risk factors and outcomes. JAMA 1992; 268:3092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/32\">",
"      O'Connor GT, Malenka DJ, Quinton H, et al. Multivariate prediction of in-hospital mortality after percutaneous coronary interventions in 1994-1996. Northern New England Cardiovascular Disease Study Group. J Am Coll Cardiol 1999; 34:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/33\">",
"      Ellis SG, Weintraub W, Holmes D, et al. Relation of operator volume and experience to procedural outcome of percutaneous coronary revascularization at hospitals with high interventional volumes. Circulation 1997; 95:2479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/34\">",
"      Moscucci M, Kline-Rogers E, Share D, et al. Simple bedside additive tool for prediction of in-hospital mortality after percutaneous coronary interventions. Circulation 2001; 104:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/35\">",
"      Qureshi MA, Safian RD, Grines CL, et al. Simplified scoring system for predicting mortality after percutaneous coronary intervention. J Am Coll Cardiol 2003; 42:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/36\">",
"      Singh M, Lennon RJ, Holmes DR Jr, et al. Correlates of procedural complications and a simple integer risk score for percutaneous coronary intervention. J Am Coll Cardiol 2002; 40:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/37\">",
"      Singh M, Rihal CS, Selzer F, et al. Validation of Mayo Clinic risk adjustment model for in-hospital complications after percutaneous coronary interventions, using the National Heart, Lung, and Blood Institute dynamic registry. J Am Coll Cardiol 2003; 42:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/38\">",
"      Singh M, Rihal CS, Lennon RJ, et al. Bedside estimation of risk from percutaneous coronary intervention: the new Mayo Clinic risk scores. Mayo Clin Proc 2007; 82:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/39\">",
"      Cavender MA, Ohman EM. What do you need to know before performing a percutaneous coronary intervention? Circulation 2008; 118:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/40\">",
"      Jeremias A, Kleiman NS, Nassif D, et al. Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the evaluation of drug eluting stents and ischemic events registry. Circulation 2008; 118:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/41\">",
"      Peterson ED, Dai D, DeLong ER, et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol 2010; 55:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/42\">",
"      Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008; 51:690.",
"     </a>",
"    </li>",
"    <li>",
"     Baim DS, Grossman W. Complications of cardiac catheterization. In: Cardiac Catheterization, Angiography and Intervention, Baim,DS, Grossman W (Eds), Williams &amp; Wilkins, Baltimore 1996. p.p.17.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/44\">",
"      Athanasiadis A, Haase KK, Wullen B, et al. Lesion morphology assessed by pre-interventional intravascular ultrasound does not predict the incidence of severe coronary artery dissections. Eur Heart J 1998; 19:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/45\">",
"      Black AJ, Namay DL, Niederman AL, et al. Tear or dissection after coronary angioplasty. Morphologic correlates of an ischemic complication. Circulation 1989; 79:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/46\">",
"      Matthews BJ, Ewels CJ, Kent KM. Coronary dissection: a predictor of restenosis? Am Heart J 1988; 115:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/47\">",
"      Huber MS, Mooney JF, Madison J, Mooney MR. Use of a morphologic classification to predict clinical outcome after dissection from coronary angioplasty. Am J Cardiol 1991; 68:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/48\">",
"      Meerkin D, Tardif JC, Bertrand OF, et al. The effects of intracoronary brachytherapy on the natural history of postangioplasty dissections. J Am Coll Cardiol 2000; 36:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/49\">",
"      Ellis SG, Roubin GS, King SB 3rd, et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 1988; 77:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/50\">",
"      Cappelletti A, Margonato A, Rosano G, et al. Short- and long-term evolution of unstented nonocclusive coronary dissection after coronary angioplasty. J Am Coll Cardiol 1999; 34:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/51\">",
"      Albertal M, Van Langenhove G, Regar E, et al. Uncomplicated moderate coronary artery dissections after balloon angioplasty: good outcome without stenting. Heart 2001; 86:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/52\">",
"      Sinclair IN, McCabe CH, Sipperly ME, Baim DS. Predictors, therapeutic options and long-term outcome of abrupt reclosure. Am J Cardiol 1988; 61:61G.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/53\">",
"      Holmes DR Jr, Holubkov R, Vlietstra RE, et al. Comparison of complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J Am Coll Cardiol 1988; 12:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/54\">",
"      Detre K, Holubkov R, Kelsey S, et al. Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981. The National Heart, Lung, and Blood Institute Registry. N Engl J Med 1988; 318:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/55\">",
"      Maehara A, Mintz GS, Bui AB, et al. Incidence, morphology, angiographic findings, and outcomes of intramural hematomas after percutaneous coronary interventions: an intravascular ultrasound study. Circulation 2002; 105:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/56\">",
"      Gruberg L, Pinnow E, Flood R, et al. Incidence, management, and outcome of coronary artery perforation during percutaneous coronary intervention. Am J Cardiol 2000; 86:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/57\">",
"      Ellis SG, Ajluni S, Arnold AZ, et al. Increased coronary perforation in the new device era. Incidence, classification, management, and outcome. Circulation 1994; 90:2725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/58\">",
"      Stankovic G, Orlic D, Corvaja N, et al. Incidence, predictors, in-hospital, and late outcomes of coronary artery perforations. Am J Cardiol 2004; 93:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/59\">",
"      Dippel EJ, Kereiakes DJ, Tramuta DA, et al. Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous management. Catheter Cardiovasc Interv 2001; 52:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/60\">",
"      Elsner M, Auch-Schwelk W, Britten M, et al. Coronary stent grafts covered by a polytetrafluoroethylene membrane. Am J Cardiol 1999; 84:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/61\">",
"      Briguori C, Nishida T, Anzuini A, et al. Emergency polytetrafluoroethylene-covered stent implantation to treat coronary ruptures. Circulation 2000; 102:3028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/62\">",
"      Choi JW, Gibson CM, Murphy SA, et al. Myonecrosis following stent placement: association between impaired TIMI myocardial perfusion grade and MRI visualization of microinfarction. Catheter Cardiovasc Interv 2004; 61:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/63\">",
"      Aliabadi D, Tilli FV, Bowers TR, et al. Incidence and angiographic predictors of side branch occlusion following high-pressure intracoronary stenting. Am J Cardiol 1997; 80:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/64\">",
"      Fischman DL, Savage MP, Leon MB, et al. Fate of lesion-related side branches after coronary artery stenting. J Am Coll Cardiol 1993; 22:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/65\">",
"      I&ntilde;iguez A, Macaya C, Alfonso F, et al. Early angiographic changes of side branches arising from a Palmaz-Schatz stented coronary segment: results and clinical implications. J Am Coll Cardiol 1994; 23:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/66\">",
"      Porto I, Selvanayagam JB, Van Gaal WJ, et al. Plaque volume and occurrence and location of periprocedural myocardial necrosis after percutaneous coronary intervention: insights from delayed-enhancement magnetic resonance imaging, thrombolysis in myocardial infarction myocardial perfusion grade analysis, and intravascular ultrasound. Circulation 2006; 114:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/67\">",
"      Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005; 294:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/68\">",
"      Caputo RP, Chafizadeh ER, Stoler RC, et al. Stent jail: a minimum-security prison. Am J Cardiol 1996; 77:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/69\">",
"      Koo BK, Kang HJ, Youn TJ, et al. Physiologic assessment of jailed side branch lesions using fractional flow reserve. J Am Coll Cardiol 2005; 46:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/70\">",
"      Leon MB, Wong SC. Intracoronary stents. A breakthrough technology or just another small step? Circulation 1994; 89:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/71\">",
"      Cantor WJ, Lazzam C, Cohen EA, et al. Failed coronary stent deployment. Am Heart J 1998; 136:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/72\">",
"      Lohavanichbutr K, Webb JG, Carere RG, et al. Mechanisms, management, and outcome of failure of delivery of coronary stents. Am J Cardiol 1999; 83:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/73\">",
"      Bolte J, Neumann U, Pfafferott C, et al. Incidence, management, and outcome of stent loss during intracoronary stenting. Am J Cardiol 2001; 88:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/74\">",
"      Sch&uuml;hlen H, Kastrati A, Dirschinger J, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 1998; 98:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/75\">",
"      Garg RK, Sear JE, Hockstad ES. Spontaneous coronary artery perforation secondary to a sirolimus-eluting stent infection. J Invasive Cardiol 2007; 19:E303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/76\">",
"      Gonda E, Edmundson A, Mann T. Late coronary stent infection: a unique complication after drug-eluting stent implantation. J Invasive Cardiol 2007; 19:E307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/77\">",
"      Kini AS, Lee P, Mitre CA, et al. Postprocedure chest pain after coronary stenting: implications on clinical restenosis. J Am Coll Cardiol 2003; 41:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/78\">",
"      Robbins MA, Marso SP, Wolski K, et al. Chest pain--a strong predictor of adverse cardiac events following precutaneous intervention (from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial [EPISENT])]. Am J Cardiol 1999; 84:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/79\">",
"      Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/80\">",
"      Muller DW, Shamir KJ, Ellis SG, Topol EJ. Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures. Am J Cardiol 1992; 69:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/81\">",
"      Carrozza JP Jr, Baim DS. Complications of directional coronary atherectomy: incidence, causes, and management. Am J Cardiol 1993; 72:47E.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/82\">",
"      Popma JJ, Satler LF, Pichard AD, et al. Vascular complications after balloon and new device angioplasty. Circulation 1993; 88:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/83\">",
"      Blankenship JC, Hellkamp AS, Aguirre FV, et al. Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. Am J Cardiol 1998; 81:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/84\">",
"      Cote AV, Berger PB, Holmes DR Jr, et al. Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab. Mayo Clin Proc 2001; 76:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/85\">",
"      Argulian E, Patel AD, Abramson JL, et al. Gender differences in short-term cardiovascular outcomes after percutaneous coronary interventions. Am J Cardiol 2006; 98:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/86\">",
"      Sadeghi HM, Grines CL, Chandra HR, et al. Percutaneous coronary interventions in octogenarians. glycoprotein IIb/IIIa receptor inhibitors' safety profile. J Am Coll Cardiol 2003; 42:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/87\">",
"      Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/88\">",
"      Antman EM. Should bivalirudin replace heparin during percutaneous coronary interventions? JAMA 2003; 289:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/89\">",
"      Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/90\">",
"      Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007; 369:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/91\">",
"      Chase AJ, Fretz EB, Warburton WP, et al. Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). Heart 2008; 94:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/92\">",
"      Jolly SS, Amlani S, Hamon M, et al. Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. Am Heart J 2009; 157:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/93\">",
"      Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet 2011; 377:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/94\">",
"      Di Mario C, Viceconte N. Radial angioplasty: worthy RIVAL, not undisputed winner. Lancet 2011; 377:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/95\">",
"      Keeley EC, Grines CL. Scraping of aortic debris by coronary guiding catheters: a prospective evaluation of 1,000 cases. J Am Coll Cardiol 1998; 32:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/96\">",
"      Dukkipati S, O'Neill WW, Harjai KJ, et al. Characteristics of cerebrovascular accidents after percutaneous coronary interventions. J Am Coll Cardiol 2004; 43:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/97\">",
"      Fuchs S, Stabile E, Kinnaird TD, et al. Stroke complicating percutaneous coronary interventions: incidence, predictors, and prognostic implications. Circulation 2002; 106:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/98\">",
"      Palmerini T, Biondi-Zoccai G, Reggiani LB, et al. Risk of stroke with coronary artery bypass graft surgery compared with percutaneous coronary intervention. J Am Coll Cardiol 2012; 60:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/99\">",
"      Sanchez PL, Rubenstein MH, Harrell LC, et al. Frequency of gross hematuria shortly after percutaneous coronary intervention. Am J Cardiol 2001; 88:A7, 71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/100\">",
"      Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995; 91:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/101\">",
"      Sch&ouml;mig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/102\">",
"      De Labriolle A, Bonello L, Lemesle G, et al. Decline in platelet count in patients treated by percutaneous coronary intervention: definition, incidence, prognostic importance, and predictive factors. Eur Heart J 2010; 31:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/103\">",
"      Addala S, Kahn JK, Moccia TF, et al. Outcome of ventricular fibrillation developing during percutaneous coronary interventions in 19,497 patients without cardiogenic shock. Am J Cardiol 2005; 96:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/104\">",
"      Mehta RH, Harjai KJ, Grines L, et al. Sustained ventricular tachycardia or fibrillation in the cardiac catheterization laboratory among patients receiving primary percutaneous coronary intervention: incidence, predictors, and outcomes. J Am Coll Cardiol 2004; 43:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/105\">",
"      Samore MH, Wessolossky MA, Lewis SM, et al. Frequency, risk factors, and outcome for bacteremia after percutaneous transluminal coronary angioplasty. Am J Cardiol 1997; 79:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/106\">",
"      Cleveland KO, Gelfand MS. Invasive staphylococcal infections complicating percutaneous transluminal coronary angioplasty: three cases and review. Clin Infect Dis 1995; 21:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/107\">",
"      Rihal CS, Sutton-Tyrrell K, Guo P, et al. Increased incidence of periprocedural complications among patients with peripheral vascular disease undergoing myocardial revascularization in the bypass angioplasty revascularization investigation. Circulation 1999; 100:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/108\">",
"      Chambers CE, Dehmer GJ, Cox DA, et al. Defining the length of stay following percutaneous coronary intervention: an expert consensus document from the Society for Cardiovascular Angiography and Interventions. Endorsed by the American College of Cardiology Foundation. Catheter Cardiovasc Interv 2009; 73:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/109\">",
"      Rao SV, Kaltenbach LA, Weintraub WS, et al. Prevalence and outcomes of same-day discharge after elective percutaneous coronary intervention among older patients. JAMA 2011; 306:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/110\">",
"      Curtis JP, Schreiner G, Wang Y, et al. All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients. J Am Coll Cardiol 2009; 54:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/48/38666/abstract/111\">",
"      Khawaja FJ, Shah ND, Lennon RJ, et al. Factors associated with 30-day readmission rates after percutaneous coronary intervention. Arch Intern Med 2012; 172:112.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1562 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_48_38666=[""].join("\n");
var outline_f37_48_38666=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H90372493\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREDICTORS OF MORTALITY AND MAJOR COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Influence of hospital and operator volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Absence of on-site cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lesion morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Short-term outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H536926950\">",
"      - NCDR CathPCI risk score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mortality at one year",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CORONARY ARTERY COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dissection and abrupt closure after PTCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Intramural hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Perforation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H277378975\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Distal embolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Side branch occlusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Stent jail",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Complications seen with stenting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Failure of stent deployment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Stent thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Stent infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MYOCARDIAL ISCHEMIA AND INFARCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Myocardial ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Emergency CABG for failed PCI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      VASCULAR COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Access site bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Attaining hemostasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Retroperitoneal bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59456800\">",
"      Radial artery access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Atheroembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      OTHER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Acute kidney injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Anticoagulation-associated bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Drop in platelet count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Ventricular arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Radiation exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H329756925\">",
"      EARLY DISCHARGE IN LOW RISK PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H168227244\">",
"      READMISSION WITHIN 30 DAYS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90372493\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26121304\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1562\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1562|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/35/21054\" title=\"figure 1\">",
"      CK levels post PTCA outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1562|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/37/34396\" title=\"table 1\">",
"      Requirements for off-site surgical backup",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/42/35500\" title=\"table 2\">",
"      Personnel and facility requirements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/4/44107\" title=\"table 3\">",
"      Requirements for primary PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/35/27196\" title=\"table 4\">",
"      Lesion-specific characteristics and outcome after balloon angiop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/36/23116\" title=\"table 5\">",
"      Risk score complications PCI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=related_link\">",
"      Antithrombotic therapy for intracoronary stent implantation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/13/13528?source=related_link\">",
"      Clinical presentation, evaluation, and treatment of renal atheroemboli",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/42/42665?source=related_link\">",
"      Complications of diagnostic cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/31/19961?source=related_link\">",
"      Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/15/31994?source=related_link\">",
"      Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/1/10263?source=related_link\">",
"      Epidemiology of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37464?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/38/18020?source=related_link\">",
"      Patient information: Heart stents and angioplasty (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40089?source=related_link\">",
"      Periprocedural bleeding in patients undergoing percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39737?source=related_link\">",
"      Periprocedural myocardial infarction following percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26538?source=related_link\">",
"      Prevention, presentation, and management of saphenous vein graft stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/62/31721?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14376?source=related_link\">",
"      Radiation dose and risk of malignancy from cardiovascular imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=related_link\">",
"      Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_48_38667="Causes of vitamin D deficiency";
var content_f37_48_38667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F58837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F58837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of vitamin D deficiency or resistance",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Deficient intake or absorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dietary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inadequate sunlight exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malabsorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small bowel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Defective 25-hydroxylation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biliary cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcoholic cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Increased catabolism of vitamin D to inactive metabolites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anticonvulsants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Loss of vitamin D binding protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nephrotic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Defective 1-alpha 25-hydroxylation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoparathyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-alpha hydroxylase deficiency (vitamin D-dependent rickets type 1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Defective target organ response to calcitriol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hereditary vitamin D-resistant rickets (vitamin D-dependent rickets, type 2)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_48_38667=[""].join("\n");
var outline_f37_48_38667=null;
var title_f37_48_38668="Usual doses inhaled GC-LABA";
var content_f37_48_38668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68143&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Usual doses of combination inhaled glucocorticoids and long-acting beta-agonists for the treatment of asthma in adolescents age 12 and older and adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Low dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Medium dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        High dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Budesonide/formoterol HFA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        80 mcg-4.5 mcg",
"       </td>",
"       <td>",
"        2 puffs twice a day",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        160 mcg-4.5 mcg",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2 puffs twice a day",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Fluticasone/salmeterol DPI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        100 mcg-50 mcg",
"       </td>",
"       <td>",
"        1 inhalation twice a day",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        250 mcg-50 mcg",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1 inhalation twice a day",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        500 mcg-50 mcg",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1 inhalation twice a day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Fluticasone/salmeterol HFA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        45 mcg-21 mcg",
"       </td>",
"       <td>",
"        2 puffs twice a day",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        115 mcg-21 mcg",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2 puffs twice a day",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        230 mcg-21 mcg",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2 puffs twice a day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Mometasone/formoterol HFA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        100 mcg-5 mcg",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2 puffs twice a day",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        200 mcg-5 mcg",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2 puffs twice a day",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    By convention, doses from metered dose inhalers are expressed as puffs, and doses from dry powder inhalers are expressed as inhalations. Do not exceed the maximum number of inhalations/puffs per day listed in the table due to the risk of toxicity from an excess dose of salmeterol or formoterol. Dose per puff or per inhalation of commercially available fixed dose combinations are according to US licensed product information.",
"    <div class=\"footnotes\">",
"     HFA: metered dose inhaler with hydrofluoroalkane propellant; DPI: dry powder inhaler.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_48_38668=[""].join("\n");
var outline_f37_48_38668=null;
var title_f37_48_38669="Contents: Hospital acquired infections";
var content_f37_48_38669=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?15/21/15710\">",
"       Infectious Diseases",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hospital acquired infections",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hospital acquired infections",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Healthcare-associated infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/34/26152\">",
"           Important sites and pathogens causing infections in long-term care facilities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/30/489\">",
"           Principles of infection control in long-term care facilities",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hospital-acquired infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/37/37464\">",
"           Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/1/34840\">",
"           Infections and antimicrobial resistance in the intensive care unit",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/14/10471\">",
"           Transfusion transmitted bacterial infection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Intravascular catheter-related infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/23/375\">",
"           Diagnosis of intravascular catheter-related infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/53/31578\">",
"           Prevention of intravascular catheter-related infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/20/7498\">",
"           Treatment of intravascular catheter-related infections",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-D3B06C0F41-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f37_48_38669=[""].join("\n");
var outline_f37_48_38669=null;
var title_f37_48_38670="Diagnosis of adrenal insufficiency";
var content_f37_48_38670=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F55897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F55897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Diagnostic approach to suspected adrenal insufficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 367px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_48_38670=[""].join("\n");
var outline_f37_48_38670=null;
var title_f37_48_38671="Bilateral pneumothoraces";
var content_f37_48_38671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bilateral pneumothoraces with accumulation of air visible in lateral as well as anteromedial aspect of lung, in radiograph taken in infant lying supine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gerardo Cabrera-Meza, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_48_38671=[""].join("\n");
var outline_f37_48_38671=null;
